Podcasts about centers

Is there really a trillion dollars a year in federal fraud? Why is Minnesota at the center of a $259 million Medicaid freeze? And could cracking down on fraud actually balance the federal budget? Today on AmperWave Daily — the administration says it's going after massive Medicaid fraud. Critics call it political retribution. The numbers being tossed around? Half a trillion… even a trillion dollars a year. Let's break it down.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the revolving door leadership at NIH's Institutes and Centers, UnitedHealthcare's controversial new Medicare Advantage policy, and a bill that would erase two decades worth of certain types of state nursing board discipline. Episode produced and hosted by Rachael Robertson. Sound engineering by

Why Centers of Influence Don't Respond to Cold Calls (And What Actually Works) Most financial advisors waste years chasing CPAs and attorneys with zero results. After 32 years coaching over 75,000 sessions with financial advisors, I'm sharing the real COI strategy that actually works. In this episode, Coach Joe reveal: ✅ The #1 mistake advisors make with COI strategies (and why 9/10 fail) ✅ Why CPAs and estate planning attorneys rarely deliver referrals ✅ Non-traditional COIs worth 10X more than CPAs (executive coaches, life transition specialists, business consultants) ✅ The 50-meeting rule: Why you need this many before measuring success ✅ My exact email template for warm introductions (never cold call) ✅ How to claim your niche so COIs actually remember and refer you ✅ The first meeting strategy: Listen, don't pitch Listen now and start building partnerships that actually convert.

Hey everybody, I just hopped straight off the treadmill with sweaty hair and a head full of aha's I couldn't wait to share. This one's a solo heart-to-heart about the moment Human Design stopped being “interesting” and became the missing puzzle piece that made my entire messy, chaotic, beautiful life finally make sense. If you've ever felt like you're slogging through mud while everyone else is sprinting… if you've wondered why constant action leaves you burned out and empty… if you've carried everyone else's energy like a human sponge… this episode is for you. We're talking open centers, four right arrows, gates 6 & 36 (yep, the chaos gates), my 3 profile, upper-limiting, feminine flow, Queen Esther, Pisces season miracles,   and how all of it points straight back to a God who designed every single part of your journey on purpose. No woo-woo, just real talk from a midlife woman who's finally stopped fighting who she was built to be and started walking in alignment instead of exhaustion. If you're navigating change and craving both practical insight AND deep faith, grab your earbuds and let's do this. Key Takeaways (perfect for show notes bullets or carousel posts) ✨ Human Design is undefeated — it literally forecasted the paths of people I admire before they even happened. ✨ My chart is wide open (zero defined centers) — I'm a giant energetic sponge, and learning to empty out other people's stuff has been life-changing. ✨ Four right arrows = full feminine flow mode. I'm not built for constant masculine hustle, and that's not a flaw, it's a feature. ✨ Gates 6 & 36 + 3 profile = I learn through chaos, failure, and “explosions.” Hello, Calamity Karen… it all makes sense now. ✨ Life unfolds at different speeds on purpose. My aligned, intuitive action creates way better results than forced grinding ever did. ✨ The Big Leap upper-limit moments? Totally explained. I was swimming against my own current. ✨ Pisces season + Purim + Queen Esther = it's miracle season. Just because you can't see what's swimming underneath doesn't mean it's not there. ✨ The shift from “frustrated with God” to “this was all part of the divine design” is everything. ✨ I've lived the heartbreak, the unseen seasons, the attacks, the restarts — that's exactly why I'm qualified to walk with you through yours. Call to Action (put this at the very bottom) If this landed in your spirit and you're thinking “I need more of this,” I'm putting together a small pilot group for women who want to understand their practical Human Design makeup through a faith-filled lens — no fluff, just real strategy, real encouragement, and real next steps. DM me or comment “DIVINE DESIGN” below and I'll send you the details. Spots will be super limited because I want it intimate and powerful. You've got a remarkable endgame, friend. The miracles are already swimming. All it takes is the knowing. Can't wait to hear which part hit you hardest — drop it in the comments or send me a voice note. I read every single one. See you in the next chapter, Karen ♡ Inspired Action Life Podcast Grounded conversations for life's in-between seasons. #HumanDesign #MidlifeWomen #MidlifeTransformation #HumanDesignCoach #FeminineFlow #AlignedLiving #MidlifeAwakening   Feeling that midlife spark but wondering why it feels like everyone's ahead? Friend, you're not behind—you're just beginning the most exciting chapter yet.

The Friday Five for February 27, 2026: [01:02] ☕Starbucks Spring 2026 Menu  [02:45]

1. Cuba Coast Guard Incident A US‑registered speedboat was fired upon by Cuban authorities, resulting in 4 deaths and 6 injuries. Cuba claims: The boat’s occupants fired first. Passengers (Cuban nationals living in the US) carried assault rifles, handguns, body armor, etc. The group was attempting armed infiltration with terrorist intent. The US position: Nothing is verified yet; US agencies are investigating. Officials (Rubio, Vance, DHS, Coast Guard) are demanding access to survivors. No indication the operation had any US government involvement. The event raises fears of a major diplomatic flashpoint, given: Historical tension (e.g., 1996 Brothers to the Rescue shootdown). Current hardline US posture toward Cuba. 2. Minnesota Medicaid Fraud Crackdown The Trump administration has paused $259.5 million in Medicaid reimbursements to Minnesota over large‑scale fraud concerns. Fraud schemes allegedly include: Paying mothers $1,000 to falsely diagnose children with autism to bill Medicaid. A provider billing for 450 days of work exceeding 24 hours/day. Centers billing for beneficiaries who were already deceased. VP JD Vance and CMS Director Dr. Oz emphasize: The fraud involves home and community‑based services that are hard to audit. Minnesota must submit a corrective action plan or risk losing up to $1 billion in funds. Providers have already been paid by Minnesota; the federal government is withholding reimbursement from the state, not from citizens. Please Hit Subscribe to this podcast Right Now. Also Please Subscribe to the The Ben Ferguson Show Podcast and Verdict with Ted Cruz Wherever You get You're Podcasts. And don't forget to follow the show on Social Media so you never miss a moment! Thanks for Listening X: https://x.com/benfergusonshowYouTube: https://www.youtube.com/@VerdictwithTedCruzSee omnystudio.com/listener for privacy information.

International scammers steal over $1 trillion a year, and now the United States is targeting the foreign networks behind them. The State Department, working together with the FBI and Justice Department, is now launching an effort to dismantle the scam networks based in various places in Asia.We'll discuss this topic and others in this episode of “Crossroads.”Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

In this episode we learn exactly what the title says. We wonder why the human services system is set up to dish money out as easily as a dog wags its tail. Lawmakers claim this way of conducting business opened the door to widespread massive fraud. We talked with Minnesota State Representative Patti Anderson whose committee assignments are as follows:Fraud Prevention and State Agency Oversight PolicyTaxesTransportation Finance and PolicySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

About this episode: The CDC has long collected and publicly reported data on infectious diseases, vaccination rates, overdose deaths, and other health topics. But in 2025, many of these datasets inexplicably went dark. In this episode: the importance of real-time data in implementing public health solutions and the potential consequences of these lapses in reporting. Guests: Janet Freilich, JD, is a professor at the Boston University School of Law. She writes and teaches in the areas of patent law, intellectual property, information law, and civil procedure. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: Unexplained Pauses in Centers for Disease Control and Prevention Surveillance: Erosion of the Public Evidence Base for Health Policy—Annals of Internal Medicine Dozens of CDC vaccination databases have been frozen under RFK Jr.—Ars Technica The Changing CDC Website—Public Health On Call (February 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

After the President's State of the Union address, Rep. Josh Gottheimer (D-New Jersey) discusses his party's response to the lengthy speech and underscores the affordability crisis facing many Americans. CNBC's Eamon Javers recaps the evening's highlights, including moments of partisan- and bipartisanship. Then, Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration's push to lower drug prices. Plus, Anthropic has changed its safety policy.  Rep. Josh Gottheimer - 21:28 Dr. Mehmet Oz - 29:44 In this episode: Josh Gottheimer, @RepJoshG Dr. Mehmet Oz, @DrOz Eamon Javers, @eamonjavers Joe Kernen, @JoeSquawk Becky Quick, @BeckyQuick Andrew Ross Sorkin, @andrewrsorkin Cameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Real Life Conversations for Christian Coaches, I sit down with Erica Vinson for a real, honest conversation about how technology has changed coaching—and how it hasn't.We've both been coaching long enough to remember dial-in phone lines, paper notes, and simple scheduling. Now we're navigating Zoom calls, AI tools, automated systems, and more options than ever before.But here's what I keep coming back to:Technology has changed how we coach. It has not changed why we coach.In this conversation, we talk through what we're seeing in the coaching space right now, including the shift from phone to video, how we think about scheduling and rhythms, and the growing presence of AI in coaching businesses.We're not offering a step-by-step guide or telling you what tools to use.We're inviting you into discernment.We talk about:How coaching platforms have evolved over timeWhy phone coaching still holds valueHow to use scheduling tools without losing marginWhat role AI can (and cannot) play in coachingCreating guardrails for your digital presenceWhy coaching remains an inside-out practiceIf you're feeling overwhelmed by all the tools available—or unsure how to move forward with clarity—this conversation is meant to steady you.You don't need every new tool.You don't need to panic about AI.You do need to stay present, grounded, and aligned with your calling.FREE RESOURCES:Listen to our sister podcast the REALIFE Practice Podcast on your Favorite Podcast AppTake the FREE Intro to Needs & Values AssessmentReady to discover what uniquely matters to YOU? CLICK HERE to take our FREE Intro to the Needs & Values Assessment.FREE Download: 4 Steps to Simplify Your CalendarReady to uncover more time on your calendar? This FREE download will help you remove what doesn't matter, so you have space for what does. Click here to get this FREE resource!OTHER RESOURCES:Check out our YouTube Channel!Prefer to watch AND listen? Check out our YouTube channel for the podcast episode on video! Make sure to subscribe so you get all the latest updates.My Book LinkTeresa's Book  Do What Matters, Live from Rest Not Rush is available. ! Banish busyness and discover a new way of being productive around what truly matters. Learn more at DoWhatMattersBook.com.LifeMapping ToolsWould you life to discover  Life Mapping tools to help you recognize and respond to God in your Story. Check out New Digital Downloads for personal or professional use  here https://www.onelifemaps.com/JOIN OUR COMMUNITY & CONNECT WITH ME:Become part of the FREE REALIFE Process® Community! Connect with Teresa and other podcast listeners, plus find additional content to help you discover your best REALIFE.Connect with your host, Teresa McCloy, on:Facebook - The REALIFE Process® with Teresa McCloyInstagram - teresa.mccloyLinkedIn - teresamccloyAbout Teresa McCloy:Teresa McCloy is the founder and creator of the REALIFE Process®, a framework designed to empower individuals and groups with the tools, training, and community needed for personal and professional growth. Through the REALIFE Process®, Teresa is on a mission to help others grow in self-awareness, establish sustainable rhythms, and enhance their influence and impact by integrating faith and work into their everyday lives. She lives with her husband of 42 years on their 5th generation family farm in central Illinois and enjoys great coffee, growing beautiful flower gardens and traveling as much as possible. About Erica Vinson:Erica Vinson helps clients walk through defining moments with confidence and courage enabling them to move forward in freedom and embrace fearless living. As an ACC Credentialed and Certified Professional Life & Leadership Coach, she uses wisdom from all 3 Centers of Intelligence to help clients gain deeper self-awareness and grow in relationships with others both personally and professionally. Erica is a certified REALIFE Process® Master Coach, an ©iEnneagram Motions of the Soul Practitioner, and has a certificate in Spiritual Transformation through the Transforming Center. She lives in the Metro East St. Louis area and enjoys spending quality time with friends and family, golfing, tennis, boating/water skiing, traveling, is a bit of a technology nerd and loves learning!

Episode Synopsis:Is the Illuminati just a group of maniacal human beings hell-bent on world domination, or is it really a secret occult group influenced by demonic forces and fueled by supernatural power centers?We talk about this and much more, including:How powerful was the Cult of Amun Ra?Why is the Cult of Amun Ra considered the engineers of the Illuminati?How is Amun Ra connected to the god Osiris?Why do we see Egyptian architecture throughout the world today?How has syncretism developed a more complete form of Satanic religion today?Original Air DateFebruary 25th, 2026Show HostsJason Spears & Christopher DeanOur PatreonConsider joining our Patreon Squad and becoming a Tier Operator to help support the show and get access to exclusive content like:Links and ResourcesStudio NotesA monthly Zoom call with Jason and Christopher And More…ORP ApparelMerch StoreConnect With UsLetsTalk@ORPpodcast.comFacebookInstagram

Finding the right funding for new ideas is challenging, especially when traditional philanthropy often favors established connections. However, open-call grant models are leveling the playing field, encouraging organizations to propose big, bold solutions that might otherwise stay under a funder's radar. In today's episode, host Josh Gryniewicz interviews Marc Moorghen from Lever for Change about the ways open calls are reshaping access to philanthropic funding. You'll learn the value of approaching major grant applications as learning opportunities, how to use expert and peer feedback to strengthen your case for support, and ways to leverage strategic storytelling to move funders to action. Want to suggest a topic, guest, or nonprofit organization for an upcoming episode? Send an email with the subject "NPFX suggestion" to contact@ipmadvancement.com. Additional Resources Lever for Change Bold Solutions Network https://leverforchange.org/bold-solutions-network Larsen Lam ICONIQ Impact Award https://leverforchange.org/open-calls/larsen-lam-iconiq-impact-award Resourcing Refugee Leadership Initiative https://www.refugeeslead.org "Something 'Amazing' Happened" (NEST360 story) https://leverforchange.org/article/impact-story/something-amazing-happened [NPFX] Authentic, Ethical, and Effective Messaging — From Theory to Practice https://www.ipmadvancement.com/npfx/authentic-ethical-and-effective-messaging-from-theory-to-practice [NPFX] How to Measure the Impact of Your Narrative Change Strategy https://www.ipmadvancement.com/npfx/how-to-measure-the-impact-of-your-narrative-change-strategy Guest Marc Moorghen serves as Vice President, Marketing Communications at Lever for Change, a nonprofit affiliate of the MacArthur Foundation. He leads strategic communications that help promote large-scale philanthropic investments to address global challenges. Since its founding, Lever for Change has influenced over $2.5 billion in grants and provided support to more than 500 organizations. In his role, Marc works closely with staff and donor partners to develop and implement mission-driven strategies that elevate issues, expand engagement, and support a growing global network of outstanding nonprofits. He also provides counsel to funders, helping shape messaging that amplifies their investments and drive long-term impact. Before joining Lever for Change, Marc founded and led On Message Communications, a consulting firm focused on strategic marketing and communications for cutting-edge nonprofits and philanthropists. Marc holds a bachelor's degree from Southampton University in the United Kingdom and master's degrees from the University of Leuven in Belgium and the University of Southern California's Annenberg School for Communication and Journalism. https://www.linkedin.com/in/moorghen/ https://leverforchange.org/ Interview Host Josh Gryniewicz is the founder and Chief Narrative Strategist at Odd Duck, a storytelling-for-social-change creative consultancy focused on impact-driven organizations. Josh is the co-author of the award-winning national bestseller, Interrupting Violence. For over a decade, he has worked in nonprofit communication. In 2018, he founded Odd Duck to combine his passions for storytelling and social change. The agency's Navigating Misinformation for Community Health framework has been shared with over a thousand community health organizations. Odd Duck has worked with nearly a hundred change-making organizations and advised hundreds more, including the Centers for Disease Control & Prevention, the Harvard School of Public Health, and the White House. https://www.linkedin.com/in/jgryniewicz/ https://oddduck.io/ https://www.interruptingviolence.com/ Connect with NPFX LinkedIn https://www.linkedin.com/showcase/npfx/ Facebook https://www.facebook.com/npfxpodcast Instagram https://www.instagram.com/npfx_podcast/ YouTube https://www.youtube.com/@ipmadvancement

In this episode, JJ Flizanes welcomes Erin Hines, a Human Design business coach (and repeat guest from West Coast Women Rising), to kick off a new series-style conversation on Human Design—what it is, why it's gaining traction, and how it can help you better understand your energy, decision-making, and natural way of operating in life and work. What You'll Learn What Human Design is and where it came from (a modern system developed in the late 1980s) How Human Design blends ancient and modern systems (astrology, I Ching, chakras + physics/biology concepts) The "science of differentiation": why your uniqueness matters and how it supports more ease in life The 5 Human Design types and what each one needs to manage energy well: Generators & Manifesting Generators: consistent energy when doing what lights you up; built to respond Projectors: here to guide; thrive by waiting for invitations and honoring rest Manifestors: here to initiate; thrive by informing and allowing cycles of burst/rest Reflectors: sensitive mirrors of environments; thrive with downtime and supportive spaces How type can reduce shame and friction (e.g., why open-ended questions can feel hard for "response-based" types) The basics of reading a Human Design chart: Type, Centers (defined vs open), and deeper layers like gates/channels Mentioned in the Episode Erin's free Human Design chart option (available many places; Erin's includes helpful click-for-explanations) Erin's "Intro to Human Design" custom report for deeper insight Erin's podcast: Rebel to Rise: Where Business Meets Human Design (includes business strategy + HD education) Connect with Erin Hines Erin's website: DarnGoodBusinessCoach.com Find Erin on: LinkedIn Listen to: Rebel to Rise: Where Business Meets Human Design  

In this episode, JJ Flizanes welcomes Erin Hines, a Human Design business coach (and repeat guest from West Coast Women Rising), to kick off a new series-style conversation on Human Design—what it is, why it's gaining traction, and how it can help you better understand your energy, decision-making, and natural way of operating in life and work. What You'll Learn What Human Design is and where it came from (a modern system developed in the late 1980s) How Human Design blends ancient and modern systems (astrology, I Ching, chakras + physics/biology concepts) The "science of differentiation": why your uniqueness matters and how it supports more ease in life The 5 Human Design types and what each one needs to manage energy well: Generators & Manifesting Generators: consistent energy when doing what lights you up; built to respond Projectors: here to guide; thrive by waiting for invitations and honoring rest Manifestors: here to initiate; thrive by informing and allowing cycles of burst/rest Reflectors: sensitive mirrors of environments; thrive with downtime and supportive spaces How type can reduce shame and friction (e.g., why open-ended questions can feel hard for "response-based" types) The basics of reading a Human Design chart: Type, Centers (defined vs open), and deeper layers like gates/channels Mentioned in the Episode Erin's free Human Design chart option (available many places; Erin's includes helpful click-for-explanations) Erin's "Intro to Human Design" custom report for deeper insight Erin's podcast: Rebel to Rise: Where Business Meets Human Design (includes business strategy + HD education) Connect with Erin Hines Erin's website: DarnGoodBusinessCoach.com Find Erin on: LinkedIn Listen to: Rebel to Rise: Where Business Meets Human Design  

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

In this episode, JJ Flizanes welcomes Erin Hines, a Human Design business coach (and repeat guest from West Coast Women Rising), to kick off a new series-style conversation on Human Design—what it is, why it's gaining traction, and how it can help you better understand your energy, decision-making, and natural way of operating in life and work. What You'll Learn What Human Design is and where it came from (a modern system developed in the late 1980s) How Human Design blends ancient and modern systems (astrology, I Ching, chakras + physics/biology concepts) The "science of differentiation": why your uniqueness matters and how it supports more ease in life The 5 Human Design types and what each one needs to manage energy well: Generators & Manifesting Generators: consistent energy when doing what lights you up; built to respond Projectors: here to guide; thrive by waiting for invitations and honoring rest Manifestors: here to initiate; thrive by informing and allowing cycles of burst/rest Reflectors: sensitive mirrors of environments; thrive with downtime and supportive spaces How type can reduce shame and friction (e.g., why open-ended questions can feel hard for "response-based" types) The basics of reading a Human Design chart: Type, Centers (defined vs open), and deeper layers like gates/channels Mentioned in the Episode Erin's free Human Design chart option (available many places; Erin's includes helpful click-for-explanations) Erin's "Intro to Human Design" custom report for deeper insight Erin's podcast: Rebel to Rise: Where Business Meets Human Design (includes business strategy + HD education) Connect with Erin Hines Erin's website: DarnGoodBusinessCoach.com Find Erin on: LinkedIn Listen to: Rebel to Rise: Where Business Meets Human Design  

In this episode, we sit down with Dr. John A. King—founder of Give Them A Voice Foundation—to break the silence around male sexual abuse and sex trafficking. We confront cultural myths, unpack grooming and trauma bonding, and explore how PTSD often shows up in men as anger, shutdown, hyper-independence, or shame. Drawing from insights in Trauma and Recovery and research from the Centers for Disease Control and Prevention ACE Study, this episode challenges listeners to examine minimized trauma, misplaced shame, and survival patterns that may be masking deeper wounds. Tune in to the PTSD from Male Sexual Abuse & Sex Trafficking Through a Therapist's Eyes. 

In this episode, JJ Flizanes welcomes Erin Hines, a Human Design business coach (and repeat guest from West Coast Women Rising), to kick off a new series-style conversation on Human Design—what it is, why it's gaining traction, and how it can help you better understand your energy, decision-making, and natural way of operating in life and work. What You'll Learn What Human Design is and where it came from (a modern system developed in the late 1980s) How Human Design blends ancient and modern systems (astrology, I Ching, chakras + physics/biology concepts) The "science of differentiation": why your uniqueness matters and how it supports more ease in life The 5 Human Design types and what each one needs to manage energy well: Generators & Manifesting Generators: consistent energy when doing what lights you up; built to respond Projectors: here to guide; thrive by waiting for invitations and honoring rest Manifestors: here to initiate; thrive by informing and allowing cycles of burst/rest Reflectors: sensitive mirrors of environments; thrive with downtime and supportive spaces How type can reduce shame and friction (e.g., why open-ended questions can feel hard for "response-based" types) The basics of reading a Human Design chart: Type, Centers (defined vs open), and deeper layers like gates/channels Mentioned in the Episode Erin's free Human Design chart option (available many places; Erin's includes helpful click-for-explanations) Erin's "Intro to Human Design" custom report for deeper insight Erin's podcast: Rebel to Rise: Where Business Meets Human Design (includes business strategy + HD education) Connect with Erin Hines Erin's website: DarnGoodBusinessCoach.com Find Erin on: LinkedIn Listen to: Rebel to Rise: Where Business Meets Human Design  

In this episode, JJ Flizanes welcomes Erin Hines, a Human Design business coach (and repeat guest from West Coast Women Rising), to kick off a new series-style conversation on Human Design—what it is, why it's gaining traction, and how it can help you better understand your energy, decision-making, and natural way of operating in life and work. What You'll Learn What Human Design is and where it came from (a modern system developed in the late 1980s) How Human Design blends ancient and modern systems (astrology, I Ching, chakras + physics/biology concepts) The "science of differentiation": why your uniqueness matters and how it supports more ease in life The 5 Human Design types and what each one needs to manage energy well: Generators & Manifesting Generators: consistent energy when doing what lights you up; built to respond Projectors: here to guide; thrive by waiting for invitations and honoring rest Manifestors: here to initiate; thrive by informing and allowing cycles of burst/rest Reflectors: sensitive mirrors of environments; thrive with downtime and supportive spaces How type can reduce shame and friction (e.g., why open-ended questions can feel hard for "response-based" types) The basics of reading a Human Design chart: Type, Centers (defined vs open), and deeper layers like gates/channels Mentioned in the Episode Erin's free Human Design chart option (available many places; Erin's includes helpful click-for-explanations) Erin's "Intro to Human Design" custom report for deeper insight Erin's podcast: Rebel to Rise: Where Business Meets Human Design (includes business strategy + HD education) Connect with Erin Hines Erin's website: DarnGoodBusinessCoach.com Find Erin on: LinkedIn Listen to: Rebel to Rise: Where Business Meets Human Design  

//The Wire//1100Z February 23, 2026////PRIORITY////BLUF: CARTEL WAR KICKS OFF IN MEXICO AS CJNG LEADER KILLED BY MEXICAN FORCES.// -----BEGIN TEARLINE----- -International Events-Mexico: Yesterday afternoon Mexican forces conducted a raid in the town of Tapalpa, Jalisco, with the objective of capturing Nemesio Rubén Oseguera Cervantes (Alias: "El Mencho"), the leader of the CJNG Cartel. During the operation, El Mencho was killed, which triggered heavy fighting between the Mexican government and the CJNG cartel throughout the afternoon.So far, most of the heavy fighting has been observed in Guadalajara and Puerto Vallarta, two cities which have historically served as CJNG strongholds.Immediately after Mencho's death, CJNG forces declared a general mobilization throughout Jalisco, which encompasses most of their territory. Most of the fighting throughout the afternoon took the form of knee-jerk, rapid response elements engaging Mexican authorities with small arms and crew served weapons, mostly via skirmishes in the street in various small towns scattered throughout the district. Violence is not confined to just Jalisco, burning vehicles were observed in the town of Reynosa, just across the border from McAllen, Texas.Throughout the evening, a more organized and substantial deployment was undertaken, with heavier weapons and armored vehicles being deployed to engage government forces throughout the region. In the town of Puerto Vallarta, combat actions were reported throughout the afternoon with CJNG briefly holding the city for some time. Within a few hours, Government forces rolled in hard with air support, pushing CJNG out of the city (or at least, out of fighting positions on the street) by nightfall.Throughout the countryside, many roads are impassable due to cartel forces digging anti-tank ditches across the roadway, emplacing roadblocks, and otherwise digging in for what they perceive to be a draw-out fight.-----END TEARLINE-----Analyst Comments: Throughout much of Mexico, the situation can be described as a state of pandemonium and chaos. There's no way to determine front lines or Centers of Gravity at the moment, as all of the violence observed throughout the afternoon is representative of whatever combat power local CJNG cells had at their safehouses. El Mencho was the patriarch of the CJNG, and more of a grandfather figurehead of the cartel family than an operational leader. As one might expect, killing a sicario's grandfather in such a manner has dialed the violence up to eleven.As soon as word got out that El Mencho was dead, everyone grabbed their rifles and started shooting at whatever Mexican authorities were in their area. The next few days will probably see even more organized violence as cartel leadership organizes more significantly for combat actions in the long term. Since the CJNG cartel has been allied with the Gulf Cartel for some time, violence has continued right up to the US border.Due to the rapid breakout of war throughout the region, most entities were not expecting small arms engagements on a peaceful Sunday afternoon. Cities known for heavy tourism industry are directly in the center of much of the fighting, with off-season tourists being caught in the middle of the conflict. As a reminder, Guadalajara is scheduled to host the 2026 FIFA World Cup this summer, and right now many high-level soccer matches have brought scores of tourists and sports fans to the exact district that is now host to heavy fighting.Guests at the many tourist resorts scattered throughout the region suddenly found their afternoon cocktail hour interrupted by gunfire and shrapnel, and throughout the evening most civilians throughout the region spent many hours sheltering in place, or fleeing the area if they could. The US State Department has issued shelter-in-place orders for the following areas

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

John talks with Administrator for the Centers for Medicare & Medicaid Services, Dr. Mehmet Oz, about economic improvements, healthcare reforms and global leadership under President Trump. Learn more about your ad choices. Visit megaphone.fm/adchoices

The latest Georgia Tech Research Podcast episode for the Agricultural Technology Research Program (ATRP) focuses on the Georgia Tech Diggle Lab (www.thedigglelab.com). This episode discusses cross-campus collaboration between GTRI's ATRP and GT's Diggle Lab.  The Lab's director is Dr. Steve Diggle (hence, the name).  The Diggle Lab is based in the Center for Microbial Dynamics and Infection (part of the School of Biological Sciences) at Georgia Tech.  Its primary objective is to gain a deeper understanding of microbial interactions and social behaviors, with a focus on their impact on virulence, antimicrobial resistance (AMR), and the development of therapeutic strategies. A prominent project is an investigation of the antibiotic-resistant superbug, Pseudomonas aeruginosa, which the Centers for Disease Control and Prevention (CDC) has classified as a "critical threat" in health care environments. GTRI and the Diggle Lab collaborated on research focused on bio-based wound dressings and antibiotic resistance. The collaboration has led to has developed piacens, protein-based antimicrobial structures that target specific bacteria without causing resistance.  The lab also explored ancient biotics, recreating a 1,000-year-old recipe that effectively treated Staphylococcus aureus. The collaboration aims to address antibiotic resistance and biofilm issues in poultry and industrial settings, leveraging piacens' precision and stability.

Bob Nienaber, CEO of BenefitRFP, a fintech executive benefits firm that helps HR leaders and CEOs at mid sized to large companies uncover hidden revenue, strengthen shareholder equity, and improve retention through optimized executive compensation plans.Through proprietary tools like the benefitMATRIX, Bob guides organisations to turn complex compensation structures into strategic profit drivers, revealing value that most companies never realise is there.Now, Bob's experience of running a high impact business in a demanding regulatory environment demonstrates how innovation, precision, and persistence can create millions in measurable gains for clients.And while balancing client needs, team growth, and constant innovation, he continues to lead with a commitment to clarity, impact, and long term value creation.Here's where to find more:https://www.linkedin.com/in/bobnienaberbrfphttps://benefitrfp.com/?utm_source________________________________________________Welcome to The Unforget Yourself Show where we use the power of woo and the proof of science to help you identify your blind spots, and get over your own bullshit so that you can do the fucking thing you ACTUALLY want to do!We're Mark and Katie, the founders of Unforget Yourself and the creators of the Unforget Yourself System and on this podcast, we're here to share REAL conversations about what goes on inside the heart and minds of those brave and crazy enough to start their own business. From the accidental entrepreneur to the laser-focused CEO, we find out how they got to where they are today, not by hearing the go-to story of their success, but talking about how we all have our own BS to deal with and it's through facing ourselves that we find a way to do the fucking thing.Along the way, we hope to show you that YOU are the most important asset in your business (and your life - duh!). Being a business owner is tough! With vulnerability and humor, we get to the real story behind their success and show you that you're not alone._____________________Find all our links to all the things like the socials, how to work with us and how to apply to be on the podcast here: https://linktr.ee/unforgetyourself

ENTERTAINING SHORT FILMS is a new category on the RPA Network, which features indie short films for your enjoyment! We applaud these creators! Centers around a traveling diplomat that is caught in a snowstorm and forced to take shelter with a poor Serbian family. When the family warns him of "beasts" that hunt in the night, he is quick to dismiss their fears as superstition and fairy tales - a mistake he may not have a chance to make twice.

If things couldn't get more whackadoodle, there's a new reality show (Desert Law) centered around the Pima County Sheriff's department, led by Sheriff Nanos, who's leading the investigation into Nancy Guthrie's disappearance. Plus, the mainstream media puts a hit out on content creators, Prince Andrew gets arrested, and Tyra Banks says she's ditching the modeling world after scathing Netflix documentary.    Become a Member of No Filter: ALL ACCESS: https://allaccess.supercast.com/    Shop New Merch now: https://merchlabs.com/collections/zack-peter?srsltid=AfmBOoqqnV3kfsOYPubFFxCQdpCuGjVgssGIXZRXHcLPH9t4GjiKoaio    Watch Disaster Daters: https://open.spotify.com/show/3L4GLnKwz9Uy5dT8Ey1VPi   Book a personalized message on Cameo: https://v.cameo.com/e/QxWQhpd1TIb  Learn more about your ad choices. Visit podcastchoices.com/adchoices

If things couldn't get more whackadoodle, there's a new reality show (Desert Law) centered around the Pima County Sheriff's department, led by Sheriff Nanos, who's leading the investigation into Nancy Guthrie's disappearance. Plus, the mainstream media puts a hit out on content creators, Prince Andrew gets arrested, and Tyra Banks says she's ditching the modeling world after scathing Netflix documentary.    Become a Member of No Filter: ALL ACCESS: https://allaccess.supercast.com/    Shop New Merch now: https://merchlabs.com/collections/zack-peter?srsltid=AfmBOoqqnV3kfsOYPubFFxCQdpCuGjVgssGIXZRXHcLPH9t4GjiKoaio    Watch Disaster Daters: https://open.spotify.com/show/3L4GLnKwz9Uy5dT8Ey1VPi   Book a personalized message on Cameo: https://v.cameo.com/e/QxWQhpd1TIb 

Melissa Lavasani & Jay Kopelman join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads Psychedelic Medicine Coalition, a DC-based advocacy organization focused on educating federal officials and advancing legislation around psychedelic medicine. Kopelman is CEO of Mission Within Foundation, which provides scholarships for veterans and first responders seeking psychedelic-assisted therapy retreats, often outside the United States. The conversation centers on veterans, the VA, and why that system may be the first realistic federal pathway for psychedelic care. Early Themes Lavasani describes PMC's work on Capitol Hill, including hosting events that bring lawmakers, staffers, and advocates into the same room. Her focus is steady engagement. In DC, progress often happens through repeated conversations, not headlines. Kopelman shares his background as a Marine and how his own psychedelic-assisted therapy experience led him to Mission Within. The foundation has funded more than 250 scholarships for veterans and first responders seeking treatment for PTSD, mild traumatic brain injury, depression, and addiction. They connect this work to pending veteran-focused legislation and explain why the VA matters. As a closed health system, the VA can pilot programs, gather data, and refine protocols without the pressures of private healthcare markets. Core Insights A recent Capitol Hill gathering, For Veteran Society, brought together members of Congress and leaders from the psychedelic caucus. Lavasani describes candid feedback from lawmakers. The message was clear: coordinate messaging, avoid fragmentation, and move while bipartisan interest remains. Veteran healthcare is not framed as the final goal. It is a starting point. If psychedelic therapies can demonstrate safety and effectiveness within the VA, broader adoption becomes more plausible. Kopelman raises operational realities that must be addressed: Standardized safety protocols across providers Integration support, not medication alone Clear training pathways for clinicians Real-world data beyond tightly screened clinical trials They also address recent negative headlines involving ibogaine treatment abroad. Kopelman emphasizes the need for shared learning across providers, especially when adverse events occur. Lavasani argues that inconsistency within the ecosystem can slow federal confidence. Later Discussion and Takeaways The discussion widens to federal momentum around addiction and mental health. Lavasani notes that new funding initiatives signal growing openness to innovative treatment models, even if psychedelics are not named explicitly in every announcement. Both guests stress that policy moves slowly by design. Meetings, follow-ups, and relationship building often matter more than public statements. For clinicians, researchers, operators, and advocates, the takeaways are direct: Veterans are likely the first federal pathway Public education remains essential Safety standards must be shared and transparent Integration and workforce development need attention now If psychedelic medicine enters federal systems, infrastructure will determine success. Frequently Asked Questions What do Melissa Lavasani & Jay Kopelman say about VA psychedelic policy? They argue that veteran-focused legislation offers a realistic first federal pathway for psychedelic-assisted care. Is ibogaine currently available through the VA? No. They discuss ibogaine in the context of private retreats and future possibilities, not an existing VA program. Why do Melissa Lavasani & Jay Kopelman emphasize coordination? Lawmakers respond more positively when advocates present aligned messaging and clear priorities. What safety issues are discussed by Melissa Lavasani & Jay Kopelman? They highlight the need for standardized screening, monitoring, integration support, and transparent review of adverse events. Closing Melissa Lavasani & Jay Kopelman provide a grounded look at how psychedelic policy develops inside federal systems. Their message is practical: veterans may be the first lane, but long-term success depends on coordination, safety standards, and sustained engagement. Closing This episode captures a real-time view of how federal policy could shape the next phase of the psychedelic resurgence, especially through veteran-facing legislation and VA infrastructure. Melissa Lavasani & Jay Kopelman argue that coordination, public education, and shared safety standards will shape whether access expands with credibility and care. Transcript Joe Moore: [00:00:00] Hello everybody. Welcome back to Psychedelics Today. Today we have two guests, um, got Melissa Sani from Psychedelic Medicine Coalition. We got Jake Pelman from Mission Within Foundation. We're gonna talk about I bga I became policy on a recent, uh, set of meetings in Washington, DC and, uh, all sorts of other things I'm sure. Joe Moore: But thank you both for joining me. Melissa Lavasani: Thanks for having us. Jay Kopelman: Yeah, it's a pleasure. Thanks. Joe Moore: Yeah. Um, Melissa, I wanna have you, uh, jump in. First. Can you tell us a little bit about, uh, your work and what you do at PMC? Melissa Lavasani: Yeah, so Psychedelic Medicine Coalition is, um, the only DC based Washington DC based advocacy organization dedicated to the advancing the issue of psychedelics, um, and making sure the federal government has the education they need, um, and understands the issue inside out so that they can generate good policy around, around psychedelic medicines. Melissa Lavasani: [00:01:00] Uh, we. Host Hill events. We host other convenings. Our big event every year is the Federal Summit on psychedelic medicine. Um, that's going to be May 14th this year. Um, where we talk about kinda the pressing issues that need to be talked about, uh, with government officials in the room, um, so that we can incrementally move this forward. Melissa Lavasani: Um, our presence here in Washington DC is, is really critical for this issue's success because, um, when we're talking about psychedelic medicines, um, from the federal government pers perspective, you know, they are, they are the ones that are going to initiate the policies that create a healthcare system that can properly facilitate these medicines and make sure, um, patient safety is a priority. Melissa Lavasani: And there's guardrails on this. And, um, you know, there, it's, it's really important that we have. A home base for this issue in Washington DC just [00:02:00] because, uh, this is very complicated as a lot of your viewers probably understand, and, you know, this can get lost in the mix of all the other issues that, um, lawmakers in DC are focused on right now. Melissa Lavasani: And we need to keep that consistent presence here so that this continues to be a priority for members of Congress. Joe Moore: Mm. I love this. And Jay, can you tell us a bit about yourself and mission within Foundation? Jay Kopelman: Yeah, sure. Joe, thanks. Uh, I, I am the CEO of Mission within Foundation. Prior to this, most of my adult life was spent in the military as a Marine. Jay Kopelman: And I came to this. Role after having, uh, a psychedelic assisted therapy experience myself at the mission within down in Mexico, which is where pretty much we all go. Um, we are here to help [00:03:00] provide, uh, access for veterans and first responders to be able to attend psychedelic assisted therapy retreats to treat issues like mild TBI, post-traumatic stress disorder, uh, depression, sometimes addiction at, at a very low level. Jay Kopelman: Um, and, and so we've, we've been doing this for a little more than a year now and have provided 250 plus scholarships to veterans and first responders to be able to access. These retreats and these, these lifesaving medicines. Um, we're also partnered, uh, you may or may not know with Melissa at Psychedelic Medicine Coalition to help advance education and policy, specifically the innovative, uh, therapy Centers of Excellence Act [00:04:00] that Melissa has worked for a number of years on now to bring to both Houses of Congress. Joe Moore: Thank you for that. Um, so let's chat a little bit about what this event was that just, uh, went down, uh, what, what was it two weeks ago at this point? Melissa Lavasani: Yeah. Yeah. It's called For Veteran Society and it's all, um, there's a lot of dialogue on Capitol Hill about veterans healthcare and psychedelics, but where I've been frustrated is that, you know, it was just a lot of. Melissa Lavasani: Talk about what the problems are and not a lot of talk about like how we actually propel things forward. Um, so it, at that event, I thought it was really important and we had three members of Congress there, um, Morgan Latrell, who has been a champion from day one and his time in Congress, um, having gone through the experience himself, um, [00:05:00] at Mission within, um, and then the two chairs of the psychedelic caucus, uh, Lou Correa and Jack Bergman. Melissa Lavasani: And we really got down to the nitty gritty of like w like why this has taken so long and you know, what is actually happening right now? What are the possibilities and what the roadblocks are. And it was, I thought it was a great conversation. Um, we had an interesting kind of dynamic with Latres is like a very passionate about this issue in particular. Melissa Lavasani: Um, I think it was, I think it was really. A great event. And, you know, two days later, Jack Bergman introduced his new bill for the va. Um, so it was kind of like the precursor to that bill getting introduced. And we're just excited for more and more conversations about how the government can gently guide this issue to success. Joe Moore: Hmm. Yeah. [00:06:00] That's fantastic. Um, yeah, I was a little bummed I couldn't make it, but next time, I hope. But I've heard a lot of good things and, um, it's, it sounded like there was some really important messages in, in terms of like feedback from legislators. Yeah. Yeah. Could you speak to that? Melissa Lavasani: Yeah, I mean, I think when, uh, representative Latrell was speaking, he really impressed on us a couple things. Melissa Lavasani: Um, first is that, you know, they really kind of need the advocates to. Coordinate, collaborate and come up with like a, a strategic plan, you know, without public education. Um, talking to members of Congress about this issue is, is really difficult. You know, like PMC is just one organization. We're very little mission within, very little, um, you know, we're all like, kind of new in navigating, um, this not so new issue, but new to Washington DC [00:07:00] issue. Melissa Lavasani: Um, without that public education as a baseline, uh, it's, it's, you have to spend a lot of time educating members of Congress. You know, that's like one of our things is, you know, we have to, we don't wanna tell Congress what direction to go to. We wanna provide them the information so they understand it very intimately and know how to navigate through things. Melissa Lavasani: Um, and secondly. Um, he got pretty frank with us and said, you know, we've got one cha one chance at this issue. And it's like, that's, that's kind of been like my talking point since I started. PMC is like, you have a very limited window, um, when these kind of issues pop up and they're new and they're fresh and you have a lot of the veteran community coming out and talking about it. Melissa Lavasani: And there's a lot of energy there. But now is the time to really move forward, um, with some real legislation that can be impactful. Um, but, you know, we've gotta [00:08:00] be careful. We, we forget, I think sometimes those of us who are in the ecosystem forget that our level of knowledge about these medicines and a lot of us have firsthand experience, um, with these drugs and, and our own healing journeys is, um, we forget that there is a public out there that doesn't have the level of knowledge that we all have. Melissa Lavasani: And, um. We gotta make sure that we're sticking to the right elements of, of, of what needs to happen. We need to be sure that our talking points are on track and we're not getting sideways about anything and going down roads that we don't need to talk about. It's why, um, you know, PMC is very focused on, um, moving forward veteran legislation right now. Melissa Lavasani: Not because we're a veteran organization, but because we're, we see this long-term policy track here. Um, we know where we want to get [00:09:00] to, um. Um, and watching other healthcare issues kind of come up and then go through the VA healthcare system, I think it's a really unique opportunity, um, to utilize the VA as this closed system, the biggest healthcare system in the country to evaluate, uh, how psychedelics operate within systems like that. Melissa Lavasani: And, you know, before they get into, um, other healthcare systems. What do we need to fix? What do we need to pay attention to? What's something that we're paying too much attention to that doesn't necessarily need that much attention? So it's, um, it's a real opportunity to look at psychedelic medicines within a healthcare system and obviously continue to gather the data. Melissa Lavasani: Um, Bergman's Bill emerging, uh, expanding veteran access to emerging treatments. Um, not only mandates the research, it gives the VA authority for this, uh, for running trials and, and creating programs around psychedelic medicines. But also, [00:10:00] one of the great things about it, I think, is it provides an on-ramp for veterans that don't necessarily qualify for clinical trials. Melissa Lavasani: You know, I think that's one of the biggest criticisms of clinical trials is like you're cre you're creating a vacuum for people and people don't live in a vacuum. So we don't necessarily know what psychedelics are gonna look like in real life. Um, but with this expanding veteran access bill that Bergman introduced, it provides the VA an opportunity to provide this access under. Melissa Lavasani: Um, in a, in a safe container with medical supervision while collecting data, um, while ensuring that the veteran that is going through this process has the support systems that it needs. So, um, you know, I think that there's a really unique opportunity here, and like Latrell said, like, we've got one shot at this. Melissa Lavasani: We have people's attention in Congress. Um, now's the time to start acting, and let's be really considerate and thoughtful about what we're doing with it. Joe Moore: Thanks for that, Melissa and Jay, how, [00:11:00] anything to add there on kind of your takeaways from the this, uh, last visit in dc? Jay Kopelman: Yeah, I, I think that Melissa highlighted it really well and there, there were a couple other things that I, I think, you know, you could kind of tie it all together with some other issues that we face in this country, uh, and that. Jay Kopelman: Uh, representative Correa brought up as well, but one of the things I wanted to go back and say is that veterans have kind of led this movement already, right? So, so it's a, it's a good jumping off point, right? That it's something people from both sides of the aisle, from any community in America can get behind. Jay Kopelman: You know, if you think about it, uh, in World War ii, you know, we had a million people serving our population was like, not even 200 million, but now [00:12:00] we have a population of 330 million, and at any given time there might be a million people in uniform, including the Reserve and the National Guard. So it's, it, it's an easy thing to get behind this small part of the population that is willing to sign that contract. Jay Kopelman: Where you are saying, yeah, I'm going to defend my country, possibly at the risk of my l my own life. So that's the first thing. The other thing is that the VA being a closed health system, and they don't have shareholders to answer to, they can take some risks, they can be innovative and be forward thinking in the ways that some other healthcare systems can't. Jay Kopelman: And so they have a perfect opportunity to show that they truly care for their veterans, which don't, I'm not saying they don't, but this would be an [00:13:00] opportunity to show that carrot at a whole different level. Uh, it would allow them to innovate and be a leader in something as, uh, as our friend Jim Hancock will say, you know. Jay Kopelman: When he went to the Naval Academy, they had the world's best shipbuilding program. Why doesn't the VA have the world's best care program for things like TBI and PTSD, which affects, you know, 40 something percent of all veterans, right? So, so there's, there's an opportunity here for the VA to lead from the front. Jay Kopelman: Um, the, these medicines provide, you know, reasonably lasting care where it's kind of a one and done. Whereas with the current systems, the, you know, and, and [00:14:00] again, not to denigrate the VA in any way, they're doing the best job they can with the tools in their toolbox, right? But maybe it's time for a trip to Home Depot. Jay Kopelman: Let's get some new tools. And have some new ways of fixing what's broken, which is really the way of doing things. It's not, veterans aren't broken, we are who we are. Um, but it's a, it's a way to fix what isn't working. So I, I think that, you know, given there's tremendous veteran homelessness still, you know, addiction issues, all these things that do translate to the population at large are things that can be worked on in this one system, the va that can then be shown to have efficacy, have good data, have [00:15:00] good outcomes, and, and take it to the population at large. Joe Moore: Mm-hmm. Brilliant. Thanks for that. And so there was another thing I wanted to pivot to, which is some of the recent press. So we've, um, seen a little bit of press around some, um, in one instance, some bad behavior in Mexico that a FI put out Americans thrive again, put out. And then another case there was a, a recent fatality. Joe Moore: And I think, um, both are tragic. Like we shouldn't be having to deal with this at this point. Um, but there's a lot of things that got us here. Um, it's not necessarily the operator's fault entirely, um, or even at all, honestly, like some medical interventions just carry a lot of risk. Like think, think about like, uh, how risky bypass surgery was in the nineties, right? Joe Moore: Like people were dying a lot from medical interventions and um, you know, this is a major intervention, uh, ibogaine [00:16:00] and also a lot of promise. To help people quite a bit. Um, but as of right now, there's, there's risk. And part of that risk, in my opinion, comes from the inability of organizations to necessarily collaborate. Joe Moore: Like there's no kind of convening body, sitting in the middle, allowing, um, for, and facilitating really good data sharing and learnings. Um, and I don't, I don't necessarily see an organization stepping up and being the, um, the convener for that kind of work. I've heard rumors that something's gonna happen there, and I'm, I'm hopeful I'll always wanna share my opinion on that. Joe Moore: But yeah. I don't know. Jay, from your perspective, is there anything you want to kind of speak to about, uh, these two recent incidents that Americans for Iboga kind of publicized recently? Jay Kopelman: Yeah, so I, I'll echo your sentiment, of course, that these are tragic incidents. Um, and I, [00:17:00] I think that at least in the case of the death at Ambio, AMBIO has done a very good job of talking about it, right? Jay Kopelman: They've been very honest with the information that they have. And like you said, there are risks inherent to these medicines, and it's like anything else in medicine, there are going to be risks. You know, when I went through, uh, when I, when I went through chemo, you know, there were, there are risks. You know, you don't feel well, you get sick. Jay Kopelman: Um, and, and it. There are processes in place to counter that when it happens. And there are processes and, and procedures and safety protocols in place when caring for somebody going through an ibogaine [00:18:00] journey. Uh, when I did it, we had EKG echocardiogram. You're on a heart monitor the entire time they push magnesium via iv. Jay Kopelman: You have to provide a urinalysis sample to make sure that there is nothing in your system that is going to potentially harm you. During the ibogaine, they have, uh, a cardiologist who is monitoring the heart monitors throughout the ibogaine experience. So the, the safety protocols are there. I think it's, I think it's just a matter of. Jay Kopelman: Standardizing them across all, all providers, right? Like, that would be a good thing if people would talk to one another. Um, as, as in any system, right? You've gotta have [00:19:00] some collaboration. You've gotta have standardization, you know, so, you know, they're not called standard operating procedures for nothing. Jay Kopelman: That means that in a, you know, in a given environment, everybody does things the same way. It's true in Navy and Marine Corps, air Force, army Aviation, they have standard operating procedures for every single aircraft. So if you fly, let's say the F 35 now, right? Because it's flown by the Navy, the Marine Corps, and the Air Force. Jay Kopelman: The, the emergency procedures in that airplane are standardized across all three services, so you should have the same, or, you know, with within a couple of different words, the same procedures and processes [00:20:00] across all the providers, right? Like maybe in one document you're gonna change, happy to glad and small dog to puppy, but it's still pretty much the, the same thing. Jay Kopelman: And as a service that provides scholarships to people to go access these medicines and go to these retreats, you know, my criteria is that the, this provider has to be safe. Number one, safety's paramount. It's always gotta be very safe. It should, it has to be effective. And you know, once you have those two things in place, then I have a comfort level saying, okay, yeah, we'll work with this provider. Jay Kopelman: But until those standardized processes are in place, you'll probably see these one-off things. I mean, some providers have been doing this longer than others and have [00:21:00] really figured out, you know, they've, they've cracked the code and, you know, sharing that across the spectrum would be good. Um, but just when these things happen, having a clearing house, right, where everybody can come together and talk about it, you know, like once the facts are known because. Jay Kopelman: To my knowledge, we still don't know all the facts. Like as, you know, as horrible as this is, you still have to talk about like an, has an autopsy been performed? What was found in the patient's system? You know, there, there are things there that we don't know. So we need to, we need to know that before we can start saying, okay, well this is how we can fix that, because we just don't know. Jay Kopelman: And, you know, to their credit, you know, Amio has always been safe to, to the, to the best of my knowledge. You know, I, [00:22:00] I haven't been to Ambio myself, but people that I have worked with have been there. They have observed, they have seen the process. They believe it's safe, and I trust their opinion because they've seen it elsewhere as well. Jay Kopelman: So yeah, having, having that one place where we can all come together when this happens, it, it's almost like it should be mandatory. In the military when there's a training accident, we, you know, we would have to have what's called a safety standout. And you don't do that again for a little while until you figure out, okay, how are we going to mitigate that happening again? Jay Kopelman: Believe me, you can go overboard and we don't want to do that. Like, we don't wanna just stop all care, but maybe stop detox for a week and then come back to it. [00:23:00] Joe Moore: Yeah. A dream would be, let's get like the, I don't know, 10, 20 most popular, uh, or well-known operators together somewhere and just do like a three day debrief. Joe Moore: Hey, everybody, like, here's what we see. Let's work on this together. You know how normal medicine works. And this is, it's hard because this is not necessarily, um, something people feel safe about in America talking about 'cause it's illicit here. Um, I don't understand necessarily how the operations, uh, relate to each other in Mexico, but I think that's something to like the public should dig into. Joe Moore: Like, what, what is this? And I, I'll start digging into that. Um, I, I asked a question recently of somebody like, is there some sort of like back channel signal everybody's using and there's no clear Yes. You know? Um, I think it would be good. That's just a [00:24:00] start, you know, that's like, okay, we can actually kind of say hi and watch out for this to each other. Jay Kopelman: It's not like we don't all know one another, right? Joe Moore: Yes. Jay Kopelman: Like at least three operators we're represented. At the Aspen Ibogaine meeting. So like that could be, and I think there was a panel kind of loosely related to this during Aspen Ibogaine meeting, but Joe Moore: mm-hmm. Jay Kopelman: It, you know, have a breakout where the operators can go sit down and kind of compare notes. Joe Moore: Right. Yeah. Melissa, do you have any, uh, comments on this thread here? And I, I put you on mute if you didn't see that. Um, Melissa Lavasani: all right, I'm off mute. Um, yeah, I think that Jay's hits the nail on the head with the collaboration thing. Um, I think that it's just a [00:25:00] problem across the entire ecosystem, and I think that's just a product of us being relatively new and upcoming field. Melissa Lavasani: Um, uh, it's a product of, you know. Our fundraising community is really small, so organizations feel like they are competing for the same dollars, even though their, their goals are all the same, they have different functions. Um, I think with time, I mean, let's be honest, like if we don't start collaborating and, and the federal government's moving forward, the federal government's gonna coordinate for us. Melissa Lavasani: And not, that might not necessarily be a bad thing, but, you know, we understand this issue to a whole other level that the federal government doesn't, and they're not required to understand it deeply. They just need to know how to really move forward with it the proper way. Um, but I think that it. It's really essential [00:26:00] that we all have this come together moment here so we can avoid things. Melissa Lavasani: Uh, I mean, no one's gonna die from bad advocacy. So like I've, I have a bit of an easier job. Um, but it can a, a absolutely stall efforts, um, to move things forward in Washington DC when, um, one group is saying one thing, another group is saying another thing, like, we're not quite at a point yet where we can have multiple lines of conversation and multiple things moving forward. Melissa Lavasani: Um, you know, for PMC, it's like, just let's get the first thing across the finish line. And we think that is, um, veteran healthcare. And, um, I know there's plenty of other groups out there that, that want the same thing. So, you know, I always, the reason why I put on the Federal Summit last year was I kind of hit my breaking point with a lack of collaboration and I wanted to just bring everyone in the same room and say like, all right, here are the things that we need to talk about. Melissa Lavasani: And I think the goal for this year is, um. To bring people in the same room and say, we talked about [00:27:00] we scratched the surface last year and this is where we need to really put our efforts into. And this is where the opportunities are. Um, I think that is going to, that's going to show the federal government if we can organize ourselves, that they need to take this issue really seriously. Melissa Lavasani: Um, I don't think we've done a great job at that thus far, but I think there's still plenty of time for us to get it together. Um, and I'm hoping with these two, uh, VA bills that are in the house right now and Senate is, is putting together their version of these two bills, um, so that they can move in tandem with each other. Melissa Lavasani: I think that, you know, there's an opportunity here for. Us to show the federal government as an ecosystem, Hey, we, we are so much further ahead and you know, this is what we've organized and here's how we can help you, um, that would make them buy into this issue a bit more and potentially move things forward faster. Melissa Lavasani: Uh, at this point in time, it's, I think that, [00:28:00] you know, psychedelics aren't necessarily the taboo thing that they, they used to be, but there's certainly places that need attention. Um, there's certainly conversations that need to be had, and like I said, like PMC is just one organization that can do this. Um, we can certainly organize and drive forward collaboration, but I, like we alone, cannot cover all this ground and we need the subject matter experts to collaborate with us so we can, you know, once we get in the door, we wanna bring the experts in to talk to these officials about it. Melissa Lavasani: So I. I, I really want listeners to really think about us as a convener of sorts when it comes to federal policy. Um, and you know, I think when, like for example, in the early eighties, a lot of people have made comparisons to the issue of psychedelics to the issue of AIDS research and how you have in a subject matter that's like extremely taboo and a patient population that the government [00:29:00] quite honestly didn't really care about in the early eighties. Melissa Lavasani: But what they did as an ecosystem is really organized themselves, get very clear on what they wanted the federal government to do. And within a matter of a couple years, uh, AIDS research funding was a thing that was happening. And what that, what that did was that ripple effect turned that into basically finding new therapies for something that we thought was a death, death sentence before. Melissa Lavasani: So I think. We just need to look at things in the past that have been really successful, um, and, and try to take the lessons from all of these issues and, and move forward with psychedelics. Joe Moore: Love that. And yes, we always need to be figuring out efficient approaches and where it has been successful in the past is often, um, an opportunity to mimic and, and potentially improve on that. Melissa Lavasani: Yeah. Jay Kopelman: One, one thing I think it's important to add to this part of the conversation is that, [00:30:00] you know, Melissa pointed out there are a number of organizations that are essentially doing the same thing. Jay Kopelman: Um, you know, I like to think we do things a little bit differently at Mission within Foundation in that we don't target any one specific type of service member. We, we work with all veterans. We work with first responders, but. What that leads to is that there are, as far as I've seen, nothing but good intentioned people in this space. Jay Kopelman: You know, people who really care about their patient population, they care about healing, they are trying to do a good job, and more importantly, they're trying to do good. Right? It, it, I think they all see the benefit down the road that this has, [00:31:00] pardon me, not just for veterans, but for society as a whole. Jay Kopelman: And, and ultimately that's where I would like to see this go. You know, I, I would love to see the VA take this. Take up this mantle and, and run with it and provide great data, great outcomes. You know, we are doing some data collection ourselves at Mission within foundation, albeit anecdotal based on surveys given before and after retreats. Jay Kopelman: But we're also working with, uh, Greg Fonzo down at UT Austin on a brain study he's doing that will have 40 patients in it when it's all said and done. And I think we have two more guys to put through that. Uh, and then we'll hit the 40. So there, there's a lot of good here that's being done by some really, really good people who've been doing this for a long time [00:32:00] and want to want nothing more than to, to see this. Jay Kopelman: Come to, come full circle so that we can take care of many, many, many people. Um, you know, like I say, I, I wanna work myself out of a job here. I, I just, I would love to see this happen and then I, you know, I don't have to send guys to Mexico to do this. They can go to their local VA and get the care that they need. Jay Kopelman: Um, but one thing that I don't think we've touched on yet, or regarding that is that the VA isn't designed for that. So it's gonna be a pretty big lift to get the right types of providers into the va with the knowledge, right, with the institutional knowledge of how this should be done, what is safe, what is effective, um, and then it, it's not just providing these medicines to [00:33:00] people and sending them home. Jay Kopelman: You don't just do that, you've gotta have the right therapists on the backend who can provide the integration coaching to the folks who are receiving these medicines. And I'm not just talking, I bga, even with MDMA and psilocybin, you should have a proper period of integration. It helps you to understand how this is going to affect you, what it, what the experience really meant, you know, because it's very difficult sometimes to just interpret it on your own. Jay Kopelman: And so what the experience was and what it meant to you. And, and so it will take some time to spin all that up. But once it's, once it's in place, you know, the sky's the limit. I think. Joe Moore: Kinda curious Jay, about what's, what's going on with Ibogaine at the federal level. Is there anything at VA right now? [00:34:00] Jay Kopelman: At the va? No, not with ibogaine. And, you know, uh, we, we send people specifically for IBOGAINE and five MEO, right? And, and so that, that doesn't preclude my interest in seeing this legislation passed, right? Jay Kopelman: Because it, it will start with something like MDMA or psilocybin, but ultimately it could grow to iboga, right? It the think about the cost savings at, at the va, even with psilocybin, right? Where you could potentially treat somebody with a very inexpensive dose of psilocybin or, or iboga one time, and then you, you don't have to treat them again. Jay Kopelman: Now, if I were, uh, you know, a VA therapist who's not trained in psychedelic trauma therapy. I might be worried [00:35:00] about job security, but it's like with anything, right? Like ultimately it will open pathways for new people to get that training or the existing people to get that training and, and stay on and do that work. Jay Kopelman: Um, which only adds another arrow to their quiver as far as I'm concerned, because this is coming and we're gonna need the people. It's just like ai, right? Like ai, yeah. Some people are gonna lose some jobs initially, and that's unfortunate. But productivity ultimately across all industries will increase and new jobs will be created as a result of that. Jay Kopelman: I mean, I was watching Squawk Box one morning. They were talking about the AI revolution and how there's gonna be a need for 500,000 electricians to. Build these systems that are going to work with the AI [00:36:00] supercomputers and, and so, Joe Moore: mm-hmm. Jay Kopelman: Where, where an opportunity may be lost. I think several more can be gained going forward. Melissa Lavasani: And just to add on what Jay just said there, there's nothing specific going on with Ibogaine at, at the va, but I think this administration is, is taking a real look at addiction in particular. Uh, they just launched, uh, a new initiative, uh, that's really centered on addiction treatments called the Great American Recovery. Melissa Lavasani: And, um, they're dedicating a hundred million dollars towards treating addiction as like a chronic treatable disease and not necessarily a law enforcement issue. So, um, in that initiative there will be federal grant programs for prevention and treatment and recovery. And, um, while this isn't just for psychedelic medicines, uh, I think it's a really great opportunity for the discussion of psychedelics to get elevated to the White House. Melissa Lavasani: Um, [00:37:00] there's also, previous to this announcement last week from the White House, there's been a hundred million dollars that was dedicated at, um, at ARPA h, which is. The advanced research projects, uh, agency for healthcare, um, and that is kind of an agency that's really focused on forward looking, um, treatments and technologies, uh, for, um, a, a whole slew of. Melissa Lavasani: Of issues, but this a hundred million dollars is dedicated to mental health and addiction. So there's a lot of opportunity there as well. So we, while I think, you know, some people are talking about, oh, we need a executive order on Iboga, it's like, well, you know, the, the president is thinking, um, about, you know, what issues can land with his, uh, voting block. Melissa Lavasani: And I think it's, I don't think we necessarily need a specific executive order on Iboga to call this a success. It's like, let's look at what, [00:38:00] um, what's just been announced from the White House. They're, they're all in on. Thinking creatively and finding, uh, new solutions for this. And this is kind of, this aligns with, um, HHS secretaries, uh, Robert F. Melissa Lavasani: Kennedy Junior's goals when he took on this, this role of Health Secretary. Um, addiction has been a discussion that, you know, he has personal, um, a personal tie to from his own experience. And, um, I think when this administration started, there was so much like fervor around the, the dialogue of like, everyone's talking about psychedelics. Melissa Lavasani: It was Secretary Kennedy, it was, uh, secretary Collins at the va. It was FDA Commissioner Marty Macari. And I think that there's like a lot of undue frustration within folks 'cause um, you don't necessarily snap your fingers and change happens in Washington dc This is not the city for that. And it's intentionally designed to move slow so that we can avoid really big mistakes. Melissa Lavasani: Um. [00:39:00] I think we're a year into this administration and these two announcements are, are pretty huge considering, um, you know, the, we, there are known people within domestic policy council that don't, aren't necessarily supportive of psychedelic medicine. So there's a really amazing progress here, and frustrating as it might be to, um, just be waiting for this administration to make some major move. Melissa Lavasani: I think they are making major moves like for Washington, DC These, these are major moves and we just gotta figure out how we can, um, take these initiatives and apply them to the issue of psychedelic medicines. Joe Moore: Thanks, Melissa. Um, yeah, it is, it is interesting like the amount of fervor there was at the beginning. You know, we had, uh. Kind of one of my old lawyers, Matt Zorn, jumped in with the administration. Right. And, um, you know, it was, uh, really cool to [00:40:00] see and hopeful how much energy was going on. It's been a little quiet, kind of feels like a black box a little bit, but I, you know, there was, Melissa Lavasani: that's on me. Melissa Lavasani: Maybe I, we need to be more out in public about like, what's actually happening, because I feel like, like day in and day out, it's just been, you gotta just mm-hmm. Like have that constant beat with the government. Mm-hmm. And, um, it's, it's, it's not the photo ops on the hill, it's the conversations that you have. Melissa Lavasani: It's the dinner parties you go to, it's the fundraisers you attend, you know? Mm-hmm. That's why I, I kind of have to like toot my own horn with PCs. Like, we need to be present here at, at not only on the Hill, not only at the White House, but kind of in the ecosystem of Washington DC itself. There's, it's, there are like power players here. Melissa Lavasani: There are people that are connected that can get things done, like. I mean, the other last week we had a big snow storm. I walked over to my friend's house, um, to have like a little fire sesh with them and our kids, and his next door neighbor came over. He was a member of Congress. I talked about the VA bills, like [00:41:00] we're reaching out to his office now, um, to get them, um, up to speed and hopefully get their co-sponsorship for, uh, the two VA bills. Melissa Lavasani: So, I mean, it, the little conversations you have here are just as important as the big ones with the photo ops. So, um, it, it's, it's really like, you know, building up that momentum and, and finding that time where you can really strike and make something happen. Joe Moore: Mm-hmm. Yeah. Jay, anything to add there? Jay Kopelman: Yeah, I was just gonna say that, you know, I, I, I think the fervor is still there, right? Jay Kopelman: But real life happens. Melissa Lavasani: Yes, Jay Kopelman: yes. And gets in the way, right? So, Melissa Lavasani: yeah, Jay Kopelman: I, I can't imagine how many issues. Secretary Kennedy has every day much less the president. Like there's so many things that they are dealing with on a daily basis, right? It, we, we just have to work to be the squeaky wheel in, in the right way, right. Jay Kopelman: [00:42:00] With the, with the right information at the right time. Like just inundating one of these organizations with noise, it's then it be with Informa, it just becomes noise, right? It it, it doesn't help. So when we have things to say that are meaningful and impactful, we do, and Melissa does an amazing job of that. Jay Kopelman: But, you know, it, it takes time. You know, it's, you know, we're not, this is, this is like turning an aircraft carrier, not a ski boat. Melissa Lavasani: Yeah, Joe Moore: yeah, absolutely. Um, and. It's, it's understandably frustrating, I think for the public and the psychedelic public in particular because we see all this hope, you know, we continue to get frustrated at politics. It's nothing new, right? Um, and we, we wanna see more people get well immediately. [00:43:00] And I, I kind of, Jay from the veteran perspective, I do love the kind of loud voices like, you're making me go to Mexico for this. Joe Moore: I did that and you're making me leave the country for the thing that's gonna fix me. Like, no way. And barely a recognition that this is a valid treatment. You know, like, you know, that is complicated given how medicine is structured here domestically. But it's also, let's face the facts, like the drug war kind of prevented us from being able to do this research in the first place. Joe Moore: You know? Thanks Nixon. And like, how do we actually kind of correct course and say like, we need to spend appropriately on science here so we can heal our own people, including veterans and everybody really. It's a, it's a dire situation out there. Jay Kopelman: Yeah. It, it really is. Um, you know, we were talking briefly about addicts, right? Jay Kopelman: And you know, it's not sexy. People think of addicts as people who are weak-minded, [00:44:00] right? They don't have any self-control. Um, but, but look at, look at the opioid crisis, right? That Brian Hubbard was fighting against in Kentucky for all those years. That that was something that was given to the patient by a doctor that they then became dependent on, and a lot of people died from that. Jay Kopelman: And, and so you, you know, it's, I I don't think it's fair to just put all addicts in a box. Just like it's not fair to put all veterans in a box. Just like it's not fair for doctors, put all their patients in a box. We're individuals. We, we have individual needs. Our, our health is very individual. Like, I, I don't think I should be put in the same box as every other 66-year-old that my doctor sees. Jay Kopelman: It's not fair. [00:45:00] You know, if you, if you took my high school classmates and put us all in a photo, we're all gonna have different needs, right? Like, some look like they're 76, not 66. Some look like they're 56. Not like they're, we, we do things differently. We live our lives differently. And the same is true of addicts. Jay Kopelman: They come to addiction from different places. Not everybody decides they want to just try heroin at a party, and all of a sudden they're addicted. It happens in, in different ways, you know, and the whole fentanyl thing has been so daggum nefarious, right? You know, pushing fentanyl into marijuana. Jay Kopelman: Somebody's smoking a joint and all of a sudden they're addicted to fentanyl or they die. Melissa Lavasani: I think we're having a, Jay Kopelman: it's, it's just not fair to, to say everybody in this pot is the same, or everybody in this one is the same. We have [00:46:00] to look at it differently. Joe Moore: Yeah. I like to zoom one level out and kind of talk about, um, just how hurt we are as a country, as a world really, but as a country specifically, and how many people are out of work for so many. Joe Moore: Difficult reasons and away from their families for so many kind of tragic reasons. And if we can get people back to their families and back to work, a lot of these things start to self-correct, but we have to like have those interventions where we can heal folks and, and get them back. Um, yeah. And you know, everything from trauma, uh, in childhood, you know, adulthood, combat, whatever it is. Joe Moore: Like these things can put people on the sidelines. And Jay, to your point, like you get knee surgery and all of a sudden you're, you know, two years later you're on the hunt for Fentanyl daily. You know, that's tough. It's really tough. Carl Hart does a good job talking about this kind of addiction pipeline and [00:47:00] a few others do as well. Joe Moore: But it's just, you know, kind of putting it in a moral failure bucket. It's not great. I was chatting with somebody about, um, veterans, it's like you come back and you're like, what's gonna make me feel okay right now? And it's not always alcohol. Um, like this is the first thing that made me feel okay, because there's not great treatments and there's, there's a lot of improvements in this kind of like bringing people back from the field that needs to happen. Joe Moore: In my opinion. I, it seems to be shared by a lot of people, but yeah, there's, it's, it's, IGA is gonna be great. It's gonna be really important. I really can't wait for it to be at scale appropriately, but there's a lot of other things we need to fix too, um, so that we can just, you know, not have so many people we need to, you know, spend so much money healing. Joe Moore: Mm-hmm. Jay Kopelman: Yeah. You ahead with that. We don't need the president to sign an executive order to automatically legalize Ibogaine. Right. But it would be nice if he would reschedule it so that [00:48:00] then then researchers could do this research on a larger scale. You know, we could, we could now get some real data that would show the efficacy. Jay Kopelman: And it could be done in a safe environment, you know? And, and so that would be, do Joe Moore: you have any kind of figures, like, like, I've been talking about this for a while, Jay. Like, does it drop the cost a lot of doing research when we deschedule things? Jay Kopelman: I, I would imagine so, because it'll drop the cost of accessing the medicines that are being researched. Jay Kopelman: Right? You, you would have buy-in from more organizations. You know, you might even have a pharma company that comes into this, you know, look at j and j with the ketamine, right? They have, they have a nasal spray version of ketamine that's doing very well. I mean, it's probably their, their biggest revenue [00:49:00] provider for them right now. Jay Kopelman: And, and so. You know, you, it would certainly help and I think, I think it would lower costs of research to have something rescheduled rather than being schedule one. You know it, people are afraid to take chances when you're talking about Schedule one Melissa Lavasani: labs or they just don't have the money to research things that are on Schedule one. Melissa Lavasani: 'cause there's so much in an incredible amount of red tape that you have to go through and, and your facility has to be a certain way and how you contain those, uh, medicines. Oh, researching has to be in a specific container and it's just very cumbersome to research schedule one drugs. So absolutely the cost would go down. Melissa Lavasani: Um, but Joe Moore: yeah, absolutely. Less safes. Melissa Lavasani: Yeah. Joe Moore: Yes. Less uh, Melissa Lavasani: right. Joe Moore: Locked. Yeah. Um, it'll be really interesting when that happens. I'm gonna hold out faith. That we can see some [00:50:00] movement here. Um, because yeah, like why make healing more expensive than it needs to be? I think like that's potentially a protectionist move. Joe Moore: Like, I'm not, I'm not here yet, but, um, look at AbbVie's, uh, acquisition of the Gilgamesh ip. Mm-hmm. Like that's a really interesting move. I think it was $1.2 billion. Mm-hmm. So they're gonna wanna protect that investment. Um, and it's likely going to be an approved medication. Like, I don't, I don't see a world in which it's not an approved medication. Joe Moore: Um, you know, I don't know a timeline, I would say Jay Kopelman: yeah. Joe Moore: Less than six years, just given how much cash they've got. But who knows, like, I haven't followed it too closely. So, and that's an I bga derivative to be clear, everybody, um mm-hmm. If you're not, um, in, in the loop on that, which is hopeful, you know? Joe Moore: Mm-hmm. But I don't know what the efficacy is gonna be with that compared to Ibogaine and then we have to talk about the kind of proprietary molecule stuff. Um, there's like a whole bunch of things that are gonna go on here, and this is one of the reasons why I'm excited about. Federal involvement [00:51:00] because we might actually be able to have some sort of centralized manufacturer, um, or at least the VA could license three or four generic manufacturers per for instance, and that way prices aren't gonna be, you know, eight grand a dose or whatever. Joe Moore: You know, it's, Jay Kopelman: well, I think it's a very exciting time in the space. You know, I, I think that there's the opportunity for innovation. There is the opportunity for collaboration. There's the opportunity for, you know, long-term healing at a very low cost. You know, that we, we have the highest healthcare cost per capita in the world right here in the us. Jay Kopelman: And, and yet we are not the number one health system in the world. So to me, that doesn't add up. So we need to figure out a way to start. Bringing costs down for a lot of people and [00:52:00] at the same time increasing, increasing outcomes. Joe Moore: Absolutely. Yeah. There's a lot of possible outcome improvements here and, and you know, everything from relapse rates, like we hear often about people leaving a clinic and they go and overdose when they get home. Tragically, too common. I think there's everything from, you know, I'm Jay, I'm involved in an organization called the Psychedelics and Pain Association. Joe Moore: We look at chronic pain very seriously, and IGA is something we are really interested in. And if. We could have better, you know, research, there better outcome measures there. Um, you know, perhaps we can have less people on opioids to begin with from chronic pain conditions. Um, Jay Kopelman: yeah, I, I might be due for another Ibogaine journey then, because I deal with chronic pain from Jiujitsu, but, Joe Moore: oh gosh, let's Jay Kopelman: talk Joe Moore: later. Jay Kopelman: That's self inflicted. Some people would say take a month off, but Melissa Lavasani: yeah, Jay Kopelman: I'm [00:53:00] not, I'm not that smart. Joe Moore: Yeah. Um, but you know, this, uh, yeah, this whole thing is gonna be really interesting to see how it plays out. I'm endlessly hopeful pull because I'm still here. Right. I, I've been at this for almost 10 years now, very publicly, and I think we are seeing a lot of movement. Joe Moore: It's not always what we actually wanna see, but it is movement nonetheless. You know, how many people are writing on this now than there were before? Right. You know, we, we have people in New York Times writing somewhat regularly about psychedelics and. Even international media is covering it. What do we have legalization in Australia somewhat recently for psilocybin and MDMA, Czech Republic. Joe Moore: I think Germany made some moves recently. Mm-hmm. Um, really interesting to see how this is gonna just keep shifting. Um Jay Kopelman: mm-hmm. Joe Moore: And I think there's no way that we're not gonna have prescription psychedelics in three years in the United States. It pro probably more like a [00:54:00] year and a half. I don't know. Do you, are you all taking odds? Melissa Lavasani: Yeah. I mean, I think Jay Kopelman: I, I gotta check Cal sheet, see what they're saying. Melissa Lavasani: I think it's safe to say, I mean, this could even come potentially the end of this year, I think, but definitely by the end of 2027, there's gonna be at least one psychedelic that's FDA approved. Joe Moore: Yeah. Yeah. Melissa Lavasani: If you're not counting Ketamine. Joe Moore: Right. Jay Kopelman: I, I mean, I mean it mm-hmm. It, it doesn't make sense that it. Shouldn't be or wouldn't be. Right. The, we've seen the benefits. Mm-hmm. We know what they are. It's at a very low cost, but you have to keep in mind that these things, they need to be done with the right set setting and container. Right. And, and gotta be able to provide that environment. Jay Kopelman: So, but I would, I would love, like I said, I'd love to work myself out of a job here and see this happen, not just for our veterans, [00:55:00] but for everybody. Joe Moore: Mm-hmm. Um, so Melissa, is there a way people can get involved or follow PMC or how can they support your work at PMC? Melissa Lavasani: Yeah, I mean, follow us in social media. Melissa Lavasani: Um, our two biggest platforms are LinkedIn and Instagram. Um, I'm bringing my newsletter back because I'm realizing, um, you know, there is a big gap in, in kind of like the knowledge of Washington DC just in general. What's happening here, and I think, you know, part of PC's value is that we're, we are plugged into conversations that are being had, um, here in the city. Melissa Lavasani: And, you know, we do get a little insight. Um, and I think that that would really quiet a lot of, you know, the, a lot of noise that, um, exists in the, our ecosystem. If, if people just had some clarity on like, what's actually happening or happening here and what are the opportunities and, [00:56:00] um, where do we need more reinforcement? Melissa Lavasani: Um, and, and also, you know, as we're putting together public education campaign, you know. My, like, if I could get everything I wanted like that, that campaign would be this like multi-stakeholder collaborative effort, right? Where we're covering all the ground that we need to cover. We're talking to the patient groups, we're talking to traditional mental health organizations, we're talking to the medical community, we're talking to the general population. Melissa Lavasani: I think that's like another area that we, we just seem to be, um, lacking some effort in. And, you know, ultimately the veteran story's always super compelling. It pulls on your heartstrings. These are our heroes, um, of our country. Like that, that is, that is meaningful. But a lot of the veteran population is small and we need the, like a, the just.[00:57:00] Melissa Lavasani: Basic American living in middle America, um, understanding what psychedelics are so that in, in, in presenting to them the stories that they can relate to, um, because that's how you activate the public and you activate the public and you get them to see what's happening in these clinical trials, what the data's been saying, what the opportunities are with psychedelics, and then they start calling their members of Congress and saying, Hey, there is this. Melissa Lavasani: Bill sitting in Congress and why haven't you signed onto it? And that political pressure, uh, when used the right way can be really powerful. So, um, I think, you know, now we're at this really amazing moment where we have a good amount of congressional offices that are familiar enough with psychedelics that they're willing to move on it. Melissa Lavasani: Um, there's another larger group, uh, that is familiar with psychedelics and will assist and co-sponsor legislation, but there's still so many offices that we haven't been able to get to just 'cause like we don't have all the time in the world and all the manpower in the world to [00:58:00] do it. But, you know, that is one avenue is like the advocates can speak to the, the lawmakers, the experts speak to the lawmakers, and we not, we want the public engaged in this, you know, ultimately, like that's. Melissa Lavasani: Like the best form of harm reduction is having an informed public. So we are not, they're not seeing these media headlines of like, oh, this miracle cure that, um, saved my family. It's like, yes, that can happen psychedelics. I mean, person speaking personally, psychedelics did save my family. But what you miss out of that story is the incredible amount of work I put into myself and put into my mental health to this day to maintain, um, like myself, my, my own agency and like be the parent that I wanna be and be the spouse that I wanna be. Melissa Lavasani: So, um, we, we need to continue to share these stories and we need to continue to collaborate to get this message out because we're all, we're all in the same boat right now. We all want the same things. We want patients to have safe and [00:59:00] affordable access to psychedelic assisted care. Um, and, uh. We're just in the beginning here, so, um, sign up for our newsletter and we can sign up on our website and then follow us on social media. Melissa Lavasani: And, um, I anticipate more and more events, um, happening with PMC and hopefully we can scale up some of these events to be much more public facing, um, as this issue grows. So, um, I'm really excited about the future and I'm, I've been enjoying this partnership with Mission Within. Jay is such a professional and, and it really shows up when he needs to show up and, um, I look forward to more of that in the future. Joe Moore: Fantastic. And Jay, how can people follow along and support mission within Foundation? Jay Kopelman: Yeah, again, social media is gonna be a good way to do that. So we, we are also pretty heavily engaged on LinkedIn and on Instagram. Um, I do [01:00:00] share, uh, a bit of my own stuff as well. On social media. So we have social media pages for Mission within Foundation, and we have a LinkedIn page for mission within foundation. Jay Kopelman: I have my own profiles on both of those as well where people can follow along. Um, one of the other things you know that would probably help get more attention for this is if the general public was more aware of the numbers of professional athletes who are also now pursuing. I began specifically to help treat their traumatic brain injuries and the chronic traumatic encephalopathy that they've, uh, suffered as a result of their time in professional sports or even college sports. Jay Kopelman: And, you know. I people worship these athletes, and I [01:01:00] think that if more of them, like Robert Gall, were more outspoken about these treatments and the healing properties that they've provided them, that it would get even more attention. Um, I think though what Melissa said, you know, I don't wanna parrot anything she just said because she said it perfectly Right. Jay Kopelman: And I'd just be speaking to hear myself talk. Um, but being collaborative the way that we are with PMC and with Melissa is I think, the way to move the needle on this overall. And like she said, if she could get more groups involved in, in these discussions, it would, it would do wonders for us. Joe Moore: Well, thank you both so much for your hard work out there. I always appreciate it when people are showing up and doing this important, [01:02:00] sometimes boring and tedious, but nevertheless sometimes, sometimes exciting work. And um, so yeah, just thank you both and thank you both for showing up here to psychedelics today to join us and I hope we can continue to support you all in the future. Jay Kopelman: Thank you, Joe. Thank you, Joe. It's a pleasure being with you today and with Melissa, of course, always Melissa Lavasani: appreciate the time and space. Joe Moore: Thanks.  

Hannity explains exactly what an an indoctrination center is and how history repeats itself. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast episode, Jocelyn shares her family's journey after her son was diagnosed with dyslexia while living in Australia. He was falling behind in reading, and the school had few answers or resources to support him. She began to wonder if he would ever learn to read. At a Lindamood-Bell Learning Center, everything changed. Intensive, sensory-cognitive instruction gave him the foundation he needed for reading success. By the end of instruction, he was reading books on his own, including his favorite, Green Eggs and Ham. Hear how personalized instruction gave their son the opportunity to learn to his potential.  

On this episode of the Getting Smart Podcast, Victoria Andrews sits down with Dr. Justin Terry, Superintendent of Forney ISD, to discuss the groundbreaking Opportunity Center (OC) in Forney, Texas. Dr. Terry shares the vision behind this 350,000-square-foot, future-ready facility that integrates career, college, and community into one dynamic space. From entrepreneurial opportunities for students and community members to creating a vibrant third space that serves all ages, this conversation highlights how innovative design and collaboration can transform education and community engagement. Tune in to learn how Forney ISD is redefining learning and maximizing impact for its rapidly growing district. Outline (00:00) Introduction: The Opportunity Center (02:43) Designing the OC: Vision and Process (10:10) Creating a Third Space: Community Integration (15:01) Entrepreneurship and Future-Ready Skills (24:03) Innovation Within the Box (28:07) Advice for Educational Leaders Links Watch the full video here Read the full blog here LinkedIn Forney Independent School District  

In this episode of The Dish on Health IT, host Tony Schueth is joined by co-host Alix Goss and special guest Amy Gleason, Strategic Advisor to Centers for Medicare & Medicaid Services (CMS) and Administrator of the U.S. Department of Government Efficiency (DOGE) Service, for a wide-ranging discussion on how health IT modernization is evolving under a pledge-driven, incentive-backed federal strategy.The conversation begins not with policy, but with lived experience.From Emergency Room to Interoperability AdvocateAmy shares how her early career as an emergency room nurse exposed the dangers of fragmented information. Providers were expected to make critical decisions without access to complete patient histories, while patients, often in pain or distress, were unrealistically asked to recall complex medical details.That professional frustration became deeply personal when her daughter went more than a year without diagnosis for a rare autoimmune disease, juvenile dermatomyositis (JDM). Multiple specialists saw pieces of the puzzle, but no one could see the full picture across charts and settings. Amy reflects that if today's AI tools had been applied to her daughter's complete longitudinal record, the condition may have surfaced sooner.That experience shaped her philosophy. Technology must converge with policy and trust in ways that tangibly improve care.Why Pledges Instead of Rules?Tony presses on a central theme. Amy has argued that we cannot regulate our way to success. Why pursue voluntary pledges instead of federal rulemaking?Amy explains her frustration returning to government in 2025 to find interoperability policies she helped draft in 2020 still not fully effective until 2027. Seven years is an eternity in technology. Meanwhile, the industry had technically complied with numerous mandates including Meaningful Use, Cures Act APIs and CMS interoperability rules, yet many workflows still felt broken.In her view, regulation created a floor but not always real transformation.The CMS Health Tech Ecosystem Pledge was launched as a different model. The federal government used its convening power to articulate a clear vision and challenge industry to deliver minimum viable products within six to twelve months rather than years.Initially announced with roughly 60 companies, the pledge initiative has grown to more than 600 participants collaborating in working groups. The three initial patient-focused use cases include:Improving data interoperability“Killing the clipboard” through digital identity and QR-based sharingLeveraging conversational AI and personalized recommendations for chronic conditions such as diabetes and obesityAmy describes live demonstrations at a Connectathon showing OAuth-enabled data retrieval, QR ingestion into EHR workflows and AI-powered recommendations built on patient data. The goal is not perfection by the first milestone, but real-world minimum viable functionality that can iteratively improve.Alix notes that from the standards community perspective, this approach feels aligned with long-standing calls for industry-driven collaboration, though it remains early to measure widespread impact.Carrots, Sticks and Rural HealthThe discussion turns to incentives.Amy outlines the administration's carrots and sticks strategy:Stick: Enforcement of information blocking, with penalties up to $2 million per occurrenceCarrots: Financial incentives such as the $50 billion Rural Health Transformation Program and the CMS ACCESS Model, which pays for technology-enabled outcomesThe Rural Health Transformation Program directs money to states with expectations that ecosystem-aligned interoperability and app participation be incorporated into funding proposals. CMS retains oversight and clawback authority to ensure funds support rural providers.The ACCESS Model represents a significant shift. Technology-enabled care platforms can register as Medicare Part B providers and be paid for measurable outcomes in tracks such as cardiometabolic disease, musculoskeletal conditions and behavioral health. Providers remain in the loop and receive compensation for referral and care plan oversight.Alix underscores that rural providers face steep financial and workforce constraints. Standards participation, implementation and technology upgrades require resources that are often scarce. The success of these incentives will depend on whether they reduce burden rather than add to it.AI: Evolution, Risk and RealityAI becomes a central thread of the episode.Amy compares AI adoption to autonomous vehicle models. Some scenarios allow tightly controlled automation, such as medication refills, while others require a human in the loop for higher-risk decisions. She points to a Utah prescription refill pilot as an example of bounded automation, where malpractice coverage and clearly defined use cases mitigate risk.When Tony asks who owns risk in this evolving landscape, Amy emphasizes the need for light but clear regulatory pathways rather than fragmented state-by-state oversight.Patients, she notes, are already there. Millions are asking health-related questions weekly through AI tools. The more pressing issue is ensuring those tools are grounded in structured medical data rather than incomplete memory or unverified inputs.She shares a striking story. Her daughter was excluded from a clinical trial due to a misclassification of ulcerative colitis. By uploading her records into an AI model, they identified a more precise diagnosis, microscopic lymphocytic colitis, which did not disqualify her from the trial. For Amy, this demonstrates both the power and inevitability of AI use.Alix adds caution. AI is only as strong as the data beneath it. Dirty, inconsistent and poorly structured data limits performance. Standards and terminologies remain essential to fuel high-fidelity models and safeguard trust.FHIR, Deregulation and the Data FoundationThe conversation addresses an emerging tension. If regulatory burdens are being reduced, does that signal less need for structured standards like FHIR?Amy candidly admits she initially wondered whether AI might reduce the need for FHIR altogether. After discussions with labs and technologists, she concluded the opposite. Standardized data dramatically improves AI performance and reduces error.Deregulation is about removing unnecessary burden, not abandoning foundational data structures.Alix reinforces that FHIR enables discrete, normalized data capture that supports both legacy transactions and AI evolution. While future innovations may emerge, today FHIR remains the backbone for scalable interoperability.Prior Authorization and HIPAA ModernizationThe episode dives into prior authorization modernization across medical and pharmacy domains.Amy notes growing interest among pledge participants to expand into pharmacy prior authorization testing, diagnostic imaging, real-time benefit checks and bulk FHIR performance testing.Alix provides insight into ongoing work within the Designated Standards Maintenance Organizations to incorporate FHIR-based approaches into HIPAA-named standards, particularly for prior authorization. She highlights testing beyond Connectathons, including implementer communities and real-world pilot efforts.Both stress the importance of public comment periods and industry engagement, describing participation as a civic responsibility for health IT professionals.Trust as the Core EnablerThe final segment centers on trust.Amy explains that the ecosystem initiative aims to reinforce trust through:Stronger digital identity verification such as Clear, ID.me and Login.govCertification frameworks such as CARIN and DIME for patient-facing appsA new national provider directory to replace fragmented provider data sourcesTransparency dashboards showing data requests, volumes and purposeRather than replacing frameworks like TEFCA, she describes the pledge model as an accelerator layered above the regulatory floor.Transparency acts as sunlight, enabling visibility into who is accessing data and for what purpose.Final TakeawaysIn closing, Amy urges providers not to sit on the sidelines. Too often, she says, providers feel change is imposed on them. The pledge environment is designed as an open forum where they can directly shape what works or does not work in real workflows.Alix echoes the call. Standards require participation. Organizations must allocate budget and staff to engage, comment and collaborate. It truly takes a village.Tony concludes by framing the episode's core message. Regulation establishes baseline expectations, but voluntary movements can demonstrate what is possible before mandates reach the Federal Register.Across pledges, payment reform, AI evolution and trust frameworks, the episode underscores a consistent theme. Modernization in health IT depends not only on policy direction, but on shared accountability and active participation from every stakeholder in the ecosystem.Listeners are reminded that POCP is available to support organizations in understanding the implications of federal initiatives, enforcement priorities and their strategic implications. Reach out to us to set up an initial consultation. The episode closes, as always, with the reminder that Health IT is a dish best served hot.Prefer video? Catch episodes on the POCP YouTube channel

In 1980, toxic shock syndrome (TSS) emerged as a public health crisis among women who used tampons. There were hundreds of cases, and The Centers for Disease Control linked deaths from TSS to super-absorbent tampons.The Food and Drug Administration responded by assembling a ‘Tampon Task Force' in 1982 to develop safety standards. A researcher called Nancy King Reame was recruited to run the independent laboratory testing. Her work helped establish the first national absorbency standards for tampons. Golda Arthur speaks to Nancy King Reame. Eye-witness accounts brought to life by archive. Witness History is for those fascinated by the past. We take you to the events that have shaped our world through the eyes of the people who were there. For nine minutes every day, we take you back in time and all over the world, to examine wars, coups, scientific discoveries, cultural moments and much more. Recent episodes explore everything from the death of Adolf Hitler, the first spacewalk and the making of the movie Jaws, to celebrity tortoise Lonesome George, the Kobe earthquake and the invention of superglue. We look at the lives of some of the most famous leaders, artists, scientists and personalities in history, including: Eva Peron – Argentina's Evita; President Ronald Reagan and his famous ‘tear down this wall' speech; Thomas Keneally on why he wrote Schindler's List; and Jacques Derrida, France's ‘rock star' philosopher. You can learn all about fascinating and surprising stories, such as the civil rights swimming protest; the disastrous D-Day rehearsal; and the death of one of the world's oldest languages.(Photo: Tampons. Credit: Getty Images)

The U.S. Centers for Disease Control & Prevention reports that preventing adverse childhood experiences (ACEs) like abuse, neglect, household dysfunction could reduce the number of adults with depression by as much as 44%. ACEs are critical to identify and understand because they are highly common that cause lasting toxic stress that fundamentally changes brain development and health outcomes across a lifespan. Understanding them is crucial for preventing chronic diseases, mental health disorders, and, through early intervention, breaking cycles of intergenerational trauma. On today's show, we're discussing ACEs with Clare Anderson, MSW, Senior Policy Fellow Emeritus at Chapin Hall, a policy research institution in Chicago that focuses on child welfare and family well-being. Clare is a national expert on child welfare policy and practice and national thought leader on economic and concrete supports. She was among the chief architects of the effort to address trauma, ACEs, and toxic stress in children known to the child welfare system. Also joining us for the conversation is Michelle Clausen, PhD, a nurse midwife, researcher, and fellow with the Primary Care Research Training Program and post-doctoral scholar at the GW School of Medicine & Health Sciences. Her research focus is on developing interventions that incorporate trauma-informed strategies and spirituality to improve health outcomes. ◘ Related Links: CDC's About Adverse Childhood Experiences page, https://www.cdc.gov/aces/about/index.html; Adverse California Surgeon General's Clinical Advisory Committee' Childhood Experience Questionnaire for Adults, https://bit.ly/4aUJewT; California Department of Health Care Services' ACEs Aware information website, https://www.acesaware.org/; Navigating Economic Shocks: Public Policy Can Support or Stress Families with Clare Anderson, https://bit.ly/3ZH3dsA; Chapin white papers about ACEs, https://bit.ly/4kCQsc2 ◘ Transcript bit.ly/3JoA2mz ◘ This podcast features the song “Follow Your Dreams” (freemusicarchive.org/music/Scott_Ho…ur_Dreams_1918) by Scott Holmes, available under a Creative Commons Attribution-Noncommercial (01https://creativecommons.org/licenses/by-nc/4.0/) license. ◘ Disclaimer: The content and information shared in GW Integrative Medicine is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in GW Integrative Medicine represent the opinions of the host(s) and their guest(s). For medical advice, diagnosis, and/or treatment, please consult a medical professional.

Stay organized with a planner created just for insurance agents selling Medicare! We highlighting what to focus on during the first quarter of the year.   Read the text version   Download your copy of the Medicare Sales Planner!   Get Connected:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

#3 Signification Of Revelation (Compartments and Furnishings of the Tabernacle in Association with the 7 Anointing Centers)

Dr. George Tewfik, guest editor of the March ASA Monitor, and Dr. Emily Methangkool, contributor, discuss ambulatory anesthesia with Dr. Zach Deutch. Learn how ambulatory surgery centers (ASCs) are transforming care, how practicing in an ASC differs from the inpatient setting, what is on the horizon, and more. Recorded January 2026. 

In this episode of the SMFM Podcast, we continue a three-part American Heart Month series highlighting Patient Safety and Quality (PSQI) tools developed to improve cardiovascular outcomes during pregnancy and the postpartum period. Dr. Bart Staat is joined by Dr. Kelly Gibson and Dr. Ralph Burns, authors of the SMFM Checklist for Postpartum Discharge of Women with Hypertensive Disorders. The discussion focuses on how a standardized postpartum checklist can reduce preventable morbidity and mortality by ensuring consistent patient education, supporting home blood pressure monitoring, promoting timely follow-up, and improving transitions to ongoing care. The episode also explores practical implementation strategies, systems-level considerations, and the associated quality metric designed to help practices measure adherence and impact. A link to the checklist and quality metric is included in the show notes and is available on the Society for Maternal-Fetal Medicine website under Clinical Guidance → Patient Safety and Quality. https://publications.smfm.org/publications/331-society-for-maternal-fetal-medicine-special-statement-checklist/   Disclaimer: "The Public Health System Components: Clinicians who are related to Maternal-Fetal Medicine program is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award to the Society for Maternal-Fetal Medicine (SMFM) totaling $1,278,000 with 100 percent funded by CDC/HHS. The contents are those of the authors and do not necessarily represent the official views of nor endorsement, by CDC/HHS or the U.S. Government."  

In a January 28 article, Dr. Ronald Hirsch verified that the Centers for Medicare and Medicaid Services (CMS) “has no problem” with the Aetna Severity Payment policy because it “meets the Two-Midnight Rule.” However, there is more to consider than compliance with 42 CFR 412.3. Federal regulations also state Medicare Advantage organizations must comply with Traditional Medicare laws including payment criteria for inpatient admissions at 42 CFR 422.101(b)(2). So the burning question remains: Is CMS disregarding pertinent regulations that could nullify Aetna's policy?During the next live edition of the venerable Monitor Monday, the Internet broadcast, Cheryl Ericson, senior director of clinical policy and education for the Brundage Group, will address this apparent contradiction.Broadcast segments will also include these instantly recognizable features:·      Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds. ·      The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors. ·      Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.·      Legislative Update: Adam Brenman, legislative affairs liaison for Zelis, will report on current healthcare legislation.

I continue my step-by-step series on building a sandbox campaign from scratch. Following the framework of Jeff Rients' 20 Questions, this fifth installment dives into questions 4, 5, and 6 to establish the major power players in the region.I define the mightiest figures in the land, moving away from high-fantasy tropes to create characters that fit this gritty, historical-fantasy setting. Key topics discussed in this episode:The Mightiest Wizard: Why the choice of game system (like Tunnels & Trolls) fundamentally changes the flavor of magic and power for spellcasters.The Mightiest Warrior: A look at a veteran soldier whose strength comes from grit and experience rather than flashy magical equipment.The Richest Person: Meet Alfrith, the village's wealthiest resident. He's a likable but patient man, a petty gambler, and someone who takes the "honor" of a small debt very seriously.Promised Links:The 20 Questions: ⁠⁠https://jrients.blogspot.com/2011/04/twenty-quick-questions-for-your.html⁠⁠⁠Share your thoughts via:

In the Williams Broadcasting Studio join John, Williams and Shaun Drummond for this weeks golf news update from"The 19th Hole".

On this episode of The Siren Podcast, Jo is joined by former Washington Governor Jay Inslee to discuss his recent piece titled, “Don't Let ICE Freeze Voting,” where he urges Congress to ban ICE agents from the polls and protect democracy. Donald Trump has doubled down on saying that Republicans should “nationalize” elections and take control of voting centers. At the same time, former Trump adviser Steve Bannon has been making the rounds saying ICE agents will surround polling stations this November. It is certainly not difficult to imagine a scenario in which the president directs ICE to do just that, as Trump has spent his entire second term relitigating the outcome of the 2020 election, directing the FBI to raid the Fulton County elections center, and has never actually conceded the 2020 election after launching a two month-long attempt at couping the United States. Governor Inslee offers strategies and methods at containing Trump and ICE on this episode, including inserting “absolute binding limitation” within appropriations bills, a power that Democrats actually have, while providing some much needed hope: “We have agency here. We are not powerless. We have shown the ability to beat him in court and on the streets in peaceful resistance. Let me point out that we had 60 judges that stood up when Donald Trump lost the election in 2020 and he was unable to succeed in his coup attempt. And we've now had multiple wins where we have had judicial decrees against him that by and large actually have been enforced.” Make sure to tune into this important information-filled episode, right here on The Siren Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

Robert W. Malone, MD, MS, is a virologist and immunologist and an original inventor of mRNA delivery and vaccination as a technology, DNA vaccination, and multiple non-viral DNA and RNA/mRNA platform delivery technologies. He serves on the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices and is the author of multiple books, the most recent of which is “PsyWar: Enforcing the New World Order,” co-written with his wife, Dr. Jill Glasspool Malone. The Drs. Malone are the founders of the Malone Institute, which focuses on issues related to government, the biological sciences, and medicine.www.skyhorsepublishing.com/9781510782952/psywar/www.malone.newswww.malonebroadcasting.comwww.maloneinstitute.orgwww.rwmalonemd.com Perplexity: Download the app or ask Perplexity anything at https://pplx.ai/rogan. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode features a conversation with Isuru Vidanage, the Wine Buyer at Elemental Spirts Co. in Atlanta, GA. Born in Houston, TX to Sri Lankan immigrants, Isuru went to high school in Macon, GA and later moved to Atlanta for college. He earned a degree in Biology with a distinction in Biochemistry and Evolutionary Biology and Behavior followed by working at the Centers for Disease Control and Prevention in the Organic and Analytical Toxicology Branch. We talk about his work and how his team's focus was on understanding how populations within the U.S. and abroad were being exposed to pesticides. He talks about how he ultimately left the CDC to pursue other passions, and he ultimately found his way to the world of retail wine. You'll hear his insights about the Atlanta wine scene and how his love for community, culture, and cooking are helping to elevate his own wine education – I even challenge him to dream up who he would invite to a bucket list dinner party. You can follow @elementalspirits.co on Instagram to learn more about his work and see what wines he is showcasing at the shop.Recorded February 10, 2026 -----------------*** Check out our ⁠⁠MERCH SHOP⁠⁠ to directly support the show, and visit www.acorkintheroad.com for all upcoming events and press releases

Orthopedic surgery is in the middle of a quiet but powerful shift. Procedures that once required hospital admission are increasingly being performed in Ambulatory Surgery Centers (ASCs), and this change is transforming patient experience, physician autonomy, and the business of orthopedic care. In our latest podcast episode, Dr. Spector joins us to discuss why ASCs are becoming a dominant force in modern orthopedics. In this episode, we break down: Why more orthopedic procedures are moving out of hospitals. How ASCs are transforming patient experience, efficiency, and recovery. OrthoCarolina's bold strategy to double down on ASCs and physician-led care. The real financial differences between ASCs and hospitals for patients, insurers, and providers. Certificate of need, and the role it plays in ASCs. How ASCs and hospital partnerships work. A board-certified fellowship-trained Orthopedic spine surgeon, Dr. Spector has enjoyed a 17-year tenure with OrthoCarolina, holding multiple leadership positions, including Chief Executive Officer, Chief Quality Officer, member of the Executive Committee, chairman of the Quality/Value Committee, and co-fellowship director at the OrthoCarolina Spine Center. In 2020, Dr. Spector earned his MBA from Duke University Fuqua School of Business and was previously selected to participate in the American Orthopedic Association Leadership Program, conducted in collaboration with the University of Chicago Booth School of Business. Dr. Spector currently serves as a Board Member of the Lumbar Spine Research Society and previously held the position of President of the North Carolina Spine Society. Dr. Spector began serving as CEO of OrthoCarolina in 2024. Dr. Spector has continued to practice orthopedic surgery while active as the OrthoCarolina CEO.  

Read "ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature" – co-authored by Dr. Anthony L. Komaroff & W. Ian Lipkin. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1187163/full    Fatigue is the body's hard-wired response to a viral infection. In today's episode, Haylie Pomroy shares insights with Dr. Anthony L. Komaroff to examine the history of ME/CFS research, the causes and triggers of ME/CFS and other post-infectious chronic illnesses, and the abnormalities observed in the brain and autonomic nervous system among patients with ME/CFS and long COVID. Dr. Komaroff also addresses how patients have often been dismissed within the healthcare system, explains the physical and psychological processes involved in these conditions, and discusses how he and other clinicians are now moving to the forefront of diagnosis and treatment.   Register for the Integrative Medicine Luncheon featuring Dr. Payam Hakimi on  February 14, 2026. https://nova.zoom.us/meeting/register/RQnykYIKRZO-yVykmDp-YQ#/registration   Dr. Anthony L. Komaroff is a distinguished Professor of Medicine at Harvard Medical School and a Senior Physician at Brigham and Women's Hospital. He has held significant leadership roles, including Director of the Division of General Medicine and Primary Care at Brigham and Women's Hospital. Dr. Komaroff is known for his research on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and human herpesvirus infections. He has published over 270 research articles and book chapters and served on numerous advisory committees for major health organizations.   LinkedIn: https://www.linkedin.com/in/anthony-l-komaroff-64133346/  Facebook: https://web.facebook.com/anthonyl.komaroff    Solve ME: https://solvecfs.org  Open Medicine Foundation: https://www.omf.ngo  National Institutes of Health (NIH): https://www.nih.gov/mecfs/about-mecfs  Centers for Disease Control and Prevention (CDC): https://www.cdc.gov/me-cfs/about/index.html   Haylie Pomroy, Founder and CEO of The Haylie Pomroy Group, is a leading health strategist specializing in metabolism, weight loss, and integrative wellness. With over 25 years of experience, she has worked with top medical institutions and high-profile clients, developing targeted programs and supplements rooted in the "Food is Medicine" philosophy. Inspired by her own autoimmune journey, she combines expertise in nutrition, biochemistry, and patient advocacy to help others reclaim their health. She is a New York Times bestselling author of The Fast Metabolism Diet.   Learn more about Haylie Pomroy's approach to wellness through her website: https://hayliepomroy.com   Instagram: https://www.instagram.com/hayliepomroy  Facebook: https://www.facebook.com/hayliepomroy  YouTube: https://www.youtube.com/@hayliepomroy/videos  LinkedIn: https://www.linkedin.com/in/hayliepomroy/  X: https://x.com/hayliepomroy    Enjoy our show? Please leave us a 5-star review so we can bring hope and help to others. You can also watch the show on our YouTube.https://www.youtube.com/@NSU_INIM   Sign up today for our newsletter. https://nova.us4.list-manage.com/subscribe?u=419072c88a85f355f15ab1257&id=5e03a4de7d    This podcast is brought to you by the Institute for Neuro-Immune Medicine. Learn more about us here.   Website: https://www.nova.edu/nim/ Facebook: https://www.facebook.com/InstituteForNeuroImmuneMedicine Instagram: https://www.instagram.com/NSU_INIM/ Twitter: https://www.twitter.com/NSU_INIM

US Special Envoys Steve Witkoff and Jared Kushner were in Oman this past week to negotiate a revised nuclear agreement with Iran's foreign minister Abbas Araghchi, amidst the largest US naval buildup in the region since Operation Midnight Hammer. While nuclear capabilities took center stage, other topics such as Iran's ballistic missile program and support for Hamas, remained largely undiscussed, leaving unanswered questions about the stability of the region. FOX News London-based Correspondent Jonathan Savage joins to discuss the main takeaways from Friday's negotiations, explaining the historical background that led up to the talks and what they mean for the future of the middle east - and the U.S. Later, Administrator for the Centers for Medicare & Medicaid Services Dr. Mehmet Oz weighs in on the true scale of Medicaid fraud in the U.S. healthcare system. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Story 1: It's been a seat dominated by one man for over four decades but that will likely change very soon. Candidate for U.S. Senate in Kentucky, Nate Morris, explains what inspired him to run for the seat currently held by long-time incumbent Senator Mitch McConnell (R-KY) and where he stands on some of the more controversial issues in U.S. politics.Story 2: Is the NFL lacking in diversity? Will and The Crew react to a statement from NFL Commissioner Roger Goodell claiming that the league had “a lot of work to do” to achieve racial diversity among their head coaches, before investigating the disturbing recurrence of patients checking into hospitals with active artillery shells lodged in their rectums.Story 3: Administrator of the Centers for Medicare & Medicaid Services Dr. Mehmet Oz joins Will to break down his investigation into healthcare fraud, explaining how the misuse of millions of dollars in funds has been normalized by politicians like Gov. Gavin Newsom (D-CA). Administrator Dr. Oz breaks down how he identifies fraud, what he's doing to prevent it, and what makes Medicare and Medicaid such an easy target to begin with.Subscribe to ‘Will Cain Country' on YouTube here: ⁠⁠⁠⁠⁠Watch Will Cain Country!⁠⁠⁠Follow ‘Will Cain Country' on X (⁠⁠⁠@willcainshow⁠⁠⁠), Instagram (⁠⁠⁠@willcainshow⁠⁠⁠), TikTok (⁠⁠⁠@willcainshow⁠⁠⁠), and Facebook (⁠⁠⁠@willcainnews⁠⁠⁠)Follow Will on X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@WillCain Learn more about your ad choices. Visit podcastchoices.com/adchoices